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Abstract 
In Peru, treatment for latent tuberculosis infection (LTBI) with isoniazid is free for all people 
younger than 20 who have been in close contact with a person with active pulmonary 
tuberculosis (TB).  Despite the availability of this drug therapy within the context of a TB 
control program that exceeds the international standards for TB care, very few children access, 
and even fewer complete a full course of treatment.  This study was done in order to understand 
which factors contribute to latent tuberculosis infection treatment uptake and adherence, and 
whether a socio-economic intervention could improve uptake and adherence of treatment for 
latent tuberculosis infection.  The research was based on data collected from 2007-2011 in a 
large periurban shantytown outside of Lima, Peru.  The data were from a large cluster 
randomized controlled trial called Innovative Socio-economic Interventions Against Tuberculosis 
(ISIAT).  First, a large database of TB treatment cards was analyzed for LTBI treatment uptake 
and utilization in individual contacts in the monitoring (control) group (n=3226).  Age range of 
contact, crowding in household, index case place of origin, index case abandonment, and time 
established in Lima were all significant risk factors for uptake and adherence of LTBI treatment.  
Uptake and adherence were also analyzed with respect to the intervened (n=617) versus the 
control arm of the study.  In the intervened areas, contacts were 1.74 times (95% CI [1.59, 1.87], 
p<0.001) as likely to start, and 2.64 times (95% CI [2.27, 3.07], p<0.001) as likely to complete 
LTBI treatment. 
 Keywords: latent tuberculosis, isoniazid, uptake, adherence, children, adolescents, Peru, 
South America 
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Factors Affecting Uptake of, and Adherence to, Treatment for Latent Tuberculosis  
Infection in Ventanilla, Peru 
 Mycobacterium tuberculosis is the single agent responsible for tuberculosis (TB) disease.  
M. tuberculosis is a slow-growing bacteria that is primarily transmitted via airborne droplet 
nuclei1, which can remain suspended in the air for hours (Riley, 1974).  Due to this mechanism 
of transmission, TB is predominantly a disease of the lungs.  Via dissemination through the 
blood and across tissue planes, however, TB can infect virtually any part of the body.  For 
example, TB can infect the meninges in the brain, an especially devastating condition; the spinal 
column, called Pott’s disease; and the lymph nodes of the neck, called scrofula.  Other species of 
the Mycobacterium genus may cause similar disease in humans, but none is as devastating or 
clinically important as M. tuberculosis and TB disease. 
 TB is a significant cause of morbidity and mortality in the world today.  In 2011, there 
were a total of 8.7 million estimated cases of TB, with 0.5 million estimated cases in children 
aged less than fifteen years; and 1.4 million deaths from the disease, with 64,000 of those deaths 
in children aged less than fifteen years (World Health Organization [WHO], 2012).  This was 
less than the previous World Health Organization (WHO) estimate of 8.8 million cases and 1.45 
million deaths in 2010 and represents a continued trend of decreasing prevalence since 2006 and 
decreasing incidence rates since 2002 (WHO, 2011). 
 It is estimated that approximately two billion people, 29% of the world’s population, are 
infected with TB, but do not have any active disease.  Some experts even put the number higher, 
at one third of the world’s population (Glaziou, Falzon, Floyd, & Raviglione, 2013).  This 
infected state is called latent tuberculosis infection (LTBI).  Most people with LTBI will never 
                                                 
1 Droplet nuclei are microscopic particles that form after the fluid evaporates from droplets of respiratory 
secretions formed by sneezing, coughing, or spitting (Riley, 1974). 
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progress to active disease, but the large absolute number of people infected means that those who 
do progress represent an enormous contribution to global incidence and prevalence rates (Barry 
et al., 2009).  It is notable that in high endemic settings LTBI prevalence has been calculated at 
about 50% of those exposed (Whalen et al., 2011).  This suggests that there is a heterogeneous 
and inequitable global burden of latent disease. 
 In order to further reduce rates of TB disease worldwide, it is important to choose those 
interventions that will most affect the incidence and prevalence.  Currently, in the best 
environment with high adherence, TB diagnosis and treatment can only hope to decrease the 
incidence of TB by a maximum of 10% per year (Dye, 2011).  In order to decrease the incidence 
further, the vast number of people who are latently infected (and therefore represent a reservoir 
for the disease) must be targeted.  Isoniazid provides a convenient way to do this and could 
possibly be the strongest biomedical intervention available. 
 Most TB control programs in the developing world, however, only focus on current 
WHO recommendations: contacts less than five years old, and HIV positive individuals.  Peru is 
an exception to this, recommending treatment of LTBI for all child and adolescent close contacts 
less than twenty years old, and giving physicians wide latitude in screening and treating other 
special populations (Estrategia Sanitaria Nacional de Prevencion y Control de la Tuberculosis, 
Ministerio de Salud Peru, Direccion General de Salud de las Personas, 2006). 
Statement of Purpose 
 The purpose of this literature review is to understand the history of TB disease and 
control, how LTBI plays an important role in TB disease and control, and how treating LTBI is 
important for TB control efforts worldwide.  The purpose of the original research conducted is to 
understand the current state of LTBI treatment (uptake, adherence, barriers, facilitators, and 
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opportunities for change) in a Peruvian periurban shantytown, and to analyze the impact on 
LBTI treatment uptake and adherence of a cluster randomized controlled trial of a 
socioeconomic intervention called Innovative Socio-economic Interventions Against 
Tuberculosis (ISIAT).  This paper, and the research presented herein, was conceived as a 
springboard for more in-depth analysis of the ISIAT data, as well as other avenues for research 
that might provide insights into how to improve tuberculosis control in Peru.  The specific 
research questions addressed are: 
1. What factors contribute to latent tuberculosis infection treatment uptake and adherence?  
2. Does a socio-economic intervention improve uptake and adherence of treatment for latent 
tuberculosis infection? 
Literature Review 
A Brief History of Tuberculosis Infection and Disease 
 Tuberculosis is an ancient affliction.  The Greek physician Hippocrates first described it 
in writing as phthisis, or wasting illness.  In reference to its great destructive capacity, it has been 
variously called “The Captain among these men of death”, by 17th century English preacher John 
Bunyan when the incidence rate of active TB disease in London was 1000 per 100,000 persons 
per year (Zumla et al., 2009, p. 15), and “The Great White Plague” due to the pale appearance of 
the afflicted (Dubos & Dubos, 1987, p. 10).  The oldest known record of genetically confirmed 
TB is in the fossil of a North American Bison dated to approximately 18,000 years ago 
(Rothschild et al., 2001).  Evidence of TB has been demonstrated in a 9,000 year old Neolithic 
settlement (Hershkovitz et al., 2008), and the skull of a 500,000-year-old Homo erectus fossil 
(Kappelman et al., 2008). 
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 Amrith (2002) described a first ‘wave’ of TB in the early 19th century, when populations 
began to congregate in cities.  In the early periods of this demographic shift, new economic 
theories and practices emerged.  This resulted in a growing class of urban poor, with the majority 
of the world’s population not feeling the economic benefits of the industrial revolution for some 
time.  Due to increased crowding and deteriorating sanitation, TB prevalence in London and 
Paris during this period is estimated to have been near 100 percent, with English mortuary 
registers showing the preponderance of deaths at the lower end of the socioeconomic scale 
(Farmer, 2000; Gandy, 2003).  
 As global demographic shifts continued in the early 20th century, public health 
infrastructure, sanitation and clean water became more widely available, and were soon 
correlated with a rise in living standards and a drop in the incidence of TB disease.  In 1943, 
streptomycin was isolated and shown to be an effective agent against TB.  A decade later, in 
1952, isoniazid was demonstrated as an effective anti-TB agent.  Finally, the rifamycin drug 
class was discovered in 1959 (Bush, 2010; Daniel, 2005)2.  Pyrazinamide and ethambutol, two 
other key drugs, were developed around the same time, and other second-line therapies soon 
followed.  However, the decrease in TB incidence seen at the beginning of the 20th century 
happened well before the discovery of the first effective anti-TB drugs, and the impact of 
increasing prosperity, which led to improving nutrition, decreased crowding, increased education, 
and increased access to health care had the greatest impact on decreased incidence (McKeown, 
2005).  Improved public health measures occurring around this time, such as earlier 
identification and isolation of active cases, may also have had important effects on TB 
                                                 
2 It was in the midst of these drug discoveries that the WHO was founded in 1948. In that same year it 
declared TB a priority (WHO, 1948) due to the “high prevalence and wide distribution of the problem 
throughout the world”, combined with the realistic possibility of mass vaccination campaigns (Raviglione 
& Pio, 2002, p. 775). 
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prevalence.  Undoubtedly the new therapies for TB saved many lives, however, and the 
downward trend of TB incidence continued. 
 As tuberculosis faded from prominence in wealthy corners of the world, it soon became a 
disease of the poor—those with continued low access to health services, crowding, malnutrition, 
education, and other social determinants of health (Lonnroth et al., 2010).  This also meant that 
TB got minimal attention in the developed world until it reemerged in the late 1970s through 
1990s.  A notable case from this period is New York City’s outbreak of tuberculosis in 1979, 
which has been attributed to HIV and discriminatory public policies that disproportionately 
affected poor black communities (Wallace, 2001).  This resurgence brought the specter of TB 
back to the attention of the developed world, and highlighted the importance of improved LTBI 
treatment and other TB control activities (Wallace, 2001). 
Current Epidemiology 
 Groups such as the United Nations and the WHO track TB epidemiology and have 
published goals for TB control (Table 1).  Overall incidence rates of TB disease have been 
falling since 2002 and the estimated absolute number of TB cases has been falling slowly since 
2006.  In Latin America, in particular, incidence has been declining at a much greater rate of 
3.2% (WHO, 2011).  Except for sub-Saharan Africa, the world is now on track to meet the Stop 
TB Partnership’s3 goals for 2015 (WHO, 2012).  Despite this accelerated decline, however, it 
will not be fast enough to meet the Stop TB Partnership goal of eliminating TB by 2050, even in 
Latin America (WHO, 2011).
                                                 
3 The Stop TB Partnership is an alliance of over 1000 government, non-governmental and other 
international organizations administered by the World Health Organization. The partnership was 
established in the year 2000 with the express goal of eliminating tuberculosis. 
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Table 1  
Goals, Targets, and Indicators for Global Tuberculosis Control 
 
United Nations 
Millennium Development Goals 
Stop TB Partnership Targets 
Goal 6: Combat HIV/AIDS, malaria and other 
diseases 
Target 6c: Halt and begin to reverse the 
incidence of malaria and other major diseases 
by 2015 
Indicator 6.9: Incidence, prevalence and 
death rates associated with TB 
Indicator 6.10: Proportion of TB cases 
detected and cured under DOT 
Goal: To dramatically reduce the global 
burden of TB by 2015 in line with the 
Millennium Development Goals and the Stop 
TB Partnership targets 
By 2015: Reduce prevalence and death rates 
by 50%, compared with their levels in 1990 
By 2050: Reduce the global incidence of 
active TB cases to <1 case per 1 million 
population per year 
Source: Stop TB Partnership, 2006; United Nations [UN], 2008 
 
Pathogenesis of M. tuberculosis 
 In order to understand LTBI and the rationale for policy measures concerning the 
treatment of LTBI, it is necessary to first understand TB pathogenesis and risk factors for TB 
disease.  By understanding increased risk for TB disease it is possible to understand which 
groups are in greatest need of screening for and treatment of LTBI. 
 The life cycle of M. tuberculosis in the context of TB disease has four main phases: 
infection, latency, disease and transmission (Figure 1).  Most models of TB disease identify these 
phases as they relate to individuals: susceptible to infection, latent infected, infectious with 
active disease, and recovered (Blower et al., 1995; Murray, Oxlade, & Lin, 2011).  Murray, 
Oxlade, and Lin (2011) further divides latency into fast latency, where individuals may rapidly 
progress into an active disease (infectious) state; and slow latency, where individuals are much 
less likely to convert to an active disease state after five years of infection.  As discussed 
previously, the M. tuberculosis bacillus is most easily transmitted via droplet nuclei in the air.  
Additionally M. tuberculosis is an oxygen-loving bacterium, so it preferentially infects the lungs. 
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 (Selwyn et al., 1989)    (S. K. Sharma, Mohanan, & Sharma, 2012)  
 Figure 1. Tuberculosis pathogenesis 
Modified with permission from the American College of Chest Physicians (S. K. Sharma, 
Mohanan, & Sharma, 2012) 
* Some percentage of these individuals will progress to active disease quite rapidly. These 
individuals are typically children under the age of five, or immune compromised individuals. 
(American Thoracic Society, Centers for Disease Control and Prevention, Diseases Society of 
America, 2000) 
** Varies by risk factors:  
5-10% overall risk in healthy adult (Horsburgh, 2004) 
20% in children <5 years old (Brailey, 1940; Dheda, Smit, Badri, & Pai, 2009) 
30% in HIV + (Selwyn et al., 1989) 
40% in children <2 years old (Brailey, 1940; Dheda, Smit, Badri, & Pai, 2009) 
 
It is commonly assumed that approximately 30% of healthy individuals exposed to M. 
tuberculosis will develop latent TB infection.  The data for this assumption was taken from 
several large studies done before treatment for LTBI was widely available and published in a 
recommendation by the American Thoracic Society, Centers for Disease Control and Prevention, 
and Infectious Diseases Society of America [ATS/CDC/IDSA] (2000).  Additionally, about 5-
10% of infected individuals will progress to active disease in their lifetime depending on risk 
1
**
*
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factors present (Horsburgh, 2004).  The risk of progression decreases the farther away a person 
gets from the time of infection (Mack, Migliori, Sester, & Rieder, 2009).  These assumptions 
have been reinforced by more recent mathematical modeling, which has contributed to 
contemporary WHO estimates (Dye & Williams, 2008).  It takes about three years to self-cure or 
die from active TB, with 30% of smear positive cases self-curing and 80% of culture positive, 
smear negative cases self-curing (Tiemersma, van der Werf, Borgdorff, Williams, & Nagelkerke, 
2011).  It can therefore be assumed that a certain percentage of persons with LTBI will eliminate 
the infection without treatment (Styblo, 1980), but adequate studies on this aspect have not been 
done due to the ethics of allowing a TB infection to progress naturally.  In the United States of 
America, an example of a very low endemic tuberculosis country, it is estimated that 80% of 
tuberculosis cases are due to reactivation of LTBI, and most of these cases are in foreign-born 
persons (ATS/CDC/IDSA, 2000; Geng et al., 2002).  In order to prevent the spread of TB, the 
United States has a very inclusive LTBI screening and treatment policy. 
Risk Factors 
 Risk factors for tuberculosis disease.   
In 1994 the American Thoracic Society defined risk categories for progression of TB 
disease (Table 2) (Bass et al., 1994).  Typically treatment of LTBI is recommended for the 
second and third categories.  Out of all risk factors on an individual level, young age and HIV 
greatly increase risk for TB progression and for severe or disseminated disease; young age and 
HIV infection also form part of WHO targeted recommendations for LTBI treatment (Nelson & 
Wells, 2004; Swaminathan & Rekha, 2010). 
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Table 2  
American Thoracic Society Categories of Risk in Adults and Children (1994) 
 
Category 0: No history of TB exposure, negative TST 
Category 1: There is a history of exposure but TST is negative 
Category 2: TST +, no TB symptoms, no radiological, or bacteriological evidence of disease 
Category 3: TB infection with signs and symptoms of disease 
Note: TST=tuberculin skin test; TB=tuberculosis 
  
A recent study in Kampala, Uganda estimated an attack rate4 for close contacts of persons 
with active tuberculosis disease in an endemic setting and without the benefit of treatment for 
LTBI.  In the study area, 47.4% of the members of a household had LTBI, and 6.3% of those 
(4.6% in all persons older than five) developed active TB within the span of twenty-four months 
(Whalen et al., 2011).  The risk in young children was significantly higher with a 10.1% risk of 
progression in children five and under, and 1.4% and 5.8% respectively in individuals six to 
fifteen and sixteen to twenty five years old (Whalen et al., 2011). 
 Poverty, HIV, and young age are considered the major risk factors for progression of TB 
disease (Boccia et al., 2009; Swaminathan & Rekha, 2010).  A very recent comprehensive 
review has highlighted malnutrition, diabetes, HIV/AIDS, aging, and smoking as major 
contributors to impaired immunology in the TB context (Fox & Menzies, 2013).  Another recent 
paper focusing on socioeconomic determinants identified and categorized similar risk factors, 
and listed well-studied and less well-studied risk factors (Murray et al., 2011).  Most of the social 
factors were included in the less well-studied group (Table 3). 
  
                                                 
4 An attack rate is the cumulative incidence over a certain period of time in a population.  When the 
population is the close contacts of a person with some communicable disease, as in this case, this number 
is referred to as the secondary attack rate. 
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Table 3  
Risk Factors Contributing to Tuberculosis Infection and Disease 
 
Well-studied Less well-studied 
HIV Crowding  
Smoking Housing conditions 
Indoor air pollution Migration 
Diabetes mellitus Aging 
Alcohol use Economic trends 
Body mass index Host genetics 
Young age Poverty 
Note: HIV=human immunodeficiency virus 
Source: Murray et al., 2011 
 
 Malnutrition has a detrimental effect on biological defenses against TB and increases risk 
of progression to active disease (Schaible & Kaufmann, 2007).  When combined with other 
common situations in the setting of poverty, especially crowding, one can see why TB is 
considered a disease of poverty.   
 Considering children specifically, it is well established that the risk of developing active 
disease in those infected before two years of age is approximately 20-50% and that most of these 
children will develop milliary or meningeal disease (Marais et al., 2004).  By the age of five, 
children revert to the average population risk, but by the time they are adolescents, children once 
again show an increased rate of progression to active disease, although in the absence of 
increased risk for serious extra-pulmonary manifestations (Marais et al., 2004).  Other studies 
have also reported children under five, and, to a greater degree, children under two as groups 
with high risk of progression (Brailey, 1940; Dheda & Migliori, 2011). 
 Risk factors for latent tuberculosis infection.   
Studies of LTBI have shown a high prevalence among high-exposure groups in low- and 
middle-income countries—79% in the Ivory Coast and 63% in Peru (Joshi, Reingold, Menzies, 
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& Pai, 2006).  Other studies have also established the risk for LTBI associated with being a close 
contact (Menzies & Doherty, 2006; Morrison, Pai, & Hopewell, 2008).  Risk of infection 
associated with being a close contact is further modified by the level of infectivity of, physical 
proximity to, and time in contact with the index case (Singh & Patra, 2011).  In addition to being 
a close contact, there are some complex biochemical interactions that can put the immune 
compromised at greater risk of community acquired infection, and, therefore, at a proportionately 
higher risk for TB progression (Flynn & Chan, 2001; Gupta, Kaul, Tsolaki, Kishore, & Bhakta, 
2012).   
Diagnosis of Latent Tuberculosis Infection 
 Before administering LTBI treatment it is important to exclude a possible diagnosis of 
(active) TB disease so as not to cause drug resistance via inappropriate therapy.  Active 
pulmonary TB has multiple diagnostic modalities.  Typically, it is diagnosed with sputum smear 
microscopy, but a definitive positive or negative result can only be delivered via culture, which 
can take up to sixty days (Harries & Dye, 2006; Marais, 2008).  Other tests include: a solid 
media color test (Toit et al., 2012), the Microscopically Observed Drug Susceptibility (MODS) 
test (Mendoza et al., 2011; Moore et al., 2006), and an automated PCR system called GeneXpert 
(Chen, Chen, Chen, Chien, & Chen, 2013).  Children, however, often have paucibacillary disease, 
or are incapable of producing a good sputum sample, and so will often be negative on sputum 
smear or culture, despite having active disease.  Furthermore, disease in children is often extra-
pulmonary, complicating early diagnosis.  In Peru, the standard diagnostic tool for TB in the 
LTBI assessment algorithm for children (see Appendix A) is the Stegen & Toledo criteria.  This 
criteria utilizes signs and symptoms, including a tuberculin skin test, to assign a person a score 
and categorize their risk of active disease (Montenegro et al., 2003).   
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 The next step is ideally a positive diagnosis of LTBI.  Unfortunately there is no gold 
standard for diagnosis of LTBI (Vernon, 2013).  The best modalities available are the TST and 
the interferon gamma release assay (IGRA).  Neither, however, distinguishes LTBI from active 
disease (Marais, 2008).  Benefits of IGRA are that it is not affected by Bacille de Calmette et 
Guérin (BCG) vaccination and that it may more reliably differentiate a lack of reaction due to a 
weak immune system from a true negative.  The benefit of TST is that it is much less expensive 
and requires little infrastructure.  For this reason, TST is more easily applied in developing world 
contexts.  Beyond the mentioned differences, both TST and IGRA can be interpreted 
equivalently (Trajman, Steffen, & Menzies, 2013), and most guidelines state that therapeutic 
decisions should always be aided by appropriate clinical judgment. Because of the complications 
with interpreting IGRA and TST, guidelines in Peru state that exclusion of active TB disease is 
the only necessary component for starting LTBI treatment (Estrategia Sanitaria Nacional de 
Prevencion y Control de la Tuberculosis et al., 2006). 
Biomedical Treatment of Latent Tuberculosis Infections 
 Individuals who are infected with M. tuberculosis, but do not immediately convert to active 
disease represent an important reservoir for disease.  Because LTBI and active TB disease are 
different manifestations of the same infectious agent, it was logical to borrow from the 
modalities of active TB disease treatment to treat LTBI, especially when considering drug 
resistant LTBI.  
 Treatment of TB has been simplified, standardized and promoted by the WHO as Directly 
Observed Therapy – Short Course, better known as DOTS5, since the early 1990s (Bayer & 
                                                 
5 The full DOTS strategy includes five components: (1) Secure political commitment, with adequate and 
sustained financing, (2) Ensure early case detection, and diagnosis through quality-assured bacteriology 
(3) Provide standardized treatment with supervision, and patient support (4) Ensure effective drug supply 
and management (5) Monitor and evaluate performance and impact 
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Wilkinson, 1995; Comstock, Baum, & Snider, 1979; WHO, 1999).  The chemotherapeutic 
regimen that underlies DOTS includes four first-line drugs: isoniazid (INH), rifampicin (RMP), 
pyrazinamide (PZA), and ethambutol (EMB).  Even before this standardization of TB treatment 
occurred, it became clear that, for LTBI, isoniazid was perhaps the most effective biomedical 
intervention in the fight to control and eradicate tuberculosis.  
 There is some confusion about the terminology utilized for the treatment of latent TB, 
which is done to prevent the development of active disease.  The terms isoniazid preventive 
therapy (IPT), and tuberculosis preventive therapy (TBPT), both commonly used in the literature, 
imply primary prevention, but in actuality indicate secondary prevention6.  This is due to the fact 
that for latent TB infection, the person being treated to prevent active disease is already infected.  
In the case of non-infected persons being administered the medication, it will not prevent an 
infection, but may eliminate any infection that might occur in its most incipient phases.  For this 
reason, it is preferable to use the term latent tuberculosis infection (LTBI) treatment because it 
states exactly what is intended with pharmacological prophylaxis, and is also more general, 
allowing for regimens other than isoniazid monotherapy. 
 The dosage of isoniazid is 5 mg/kg in children up to 300 mg/day, which is the maximum 
adult dose.  The drug has high efficacy, is inexpensive, widely available, and has few adverse 
effects (Cohn & El-Sadr, 2006; Enarson, Rieder, Arnadottir, & Trébucq, 2000; Stop TB 
Partnership Childhood TB Subgroup, 2007).  Studies amongst Canadian Yupik Eskimos in the 
1970s showed that isoniazid can reduce incidence rate of TB by nearly 100%, and reported 19 
years of protection after LTBI treatment (Bayer & Wilkinson, 1995; Comstock et al., 1979; 
WHO, 1999).  Then, in the 1980s a large 30-year study in children demonstrated isoniazid’s 
                                                 
6 Prevention may be primary (before infection has occurred), secondary (after infection has occurred, but 
before symptoms are apparent), or tertiary (after illness has occurred and in an effort to minimize 
morbidity and mortality). 
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unequivocal effectiveness in curing latent infection and preventing reactivation, even going so 
far as to suggest a permanent cure (Bayer & Wilkinson, 1995; Comstock et al., 1979; Franke et 
al., 2013; Hsu, 1984; WHO, 1999).  Drug trials in Bethel, Alaska in the 1960s and 1970s 
provided the first strong evidence that the drug was effective for the prevention of active disease 
in individuals with LTBI (Comstock, 1962; Comstock et al., 1979).  The Bethel isoniazid studies 
also shifted recommended length of treatment for LTBI from twelve months to 6-9 months.  
More recently combined regimens have been used including rifamycin class antibiotics, 
ethambutol, and pyrazinamide in various combinations.  Currently the WHO recommends 
targeting children under five years old who are close contacts7 of individuals8 with pulmonary 
TB, and HIV positive individuals.  In the USA and Canada all close contacts are screened for 
LTBI and treated if necessary. 
 Worldwide, most tuberculosis control programs indicate six months of LTBI treatment, 
as recommended by the WHO.  For example, in the Western South America region, both Chile 
and Ecuador follow the six-month policy.  The USA changed their policy to nine months in light 
of the Bethel isoniazid studies, which showed a small benefit of nine months over six months, 
and noted that longer than nine to twelve months adds marginal benefit (Comstock, 1999; 
Farmer & Kim, 1998).  No programs recommend longer than nine months of treatment outside 
the context of HIV infected individuals.  
 Due to its effectiveness, the WHO and the International Union Against Tuberculosis and 
Lung Disease recommend that LTBI treatment be given to all contacts of pulmonary TB cases 
who are either HIV positive, or less than five years of age without active disease (Cohn & El-
                                                 
7 The term ‘close contact’ indicates a person who has spent significant amounts of time with the TB 
patient.  In Peruvian TB policy this term is not further defined, but there is a distinction made between 
intra and extradomiciliary contacts, both of who are considered. 
8 This individual is the index case, or the initial identified person with TB disease from whom all those 
secondarily affected are supposed to have acquired the infection. 
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Sadr, 2006; Enarson et al., 2000; Stop TB Partnership Childhood TB Subgroup, 2007).  Children 
and HIV positive individuals not only represent a large reservoir of M. tuberculosis infection, but 
are also more susceptible to developing active disease than healthy adults (Marais et al., 2004).  
The WHO focuses on these groups mainly because they are relatively small, easily targeted, and 
high risk; therefore they are more cost effective to target than other high-risk groups. 
 Additionally, LTBI treatment has generally been considered cost-ineffective at the 
population level in low- and middle-income (and more often than not, high prevalence) countries 
(Dye & Floyd, 2006).  In a more recent investigation, treatment for LTBI was reported to be 
synergistic with DOTS, and, if it is applied more broadly, may make possible the 2050 goal of 
TB elimination (Dye & Williams, 2008).  The major limitation of studies concerning LTBI 
treatment in low- and middle-income countries, where the burden of disease is highest, is that 
there have not been very many of them, and many of their underlying assumptions are unreliable 
(Vernon, 2013).  It is notable that, without making it a recommendation, the WHO has stated that 
it is desirable to treat all persons with LTBI (Stop TB Partnership Childhood TB Subgroup, 
2007). 
 One concern with using isoniazid monotherapy to treat LTBI is the possibility of 
increasing drug resistance.  A 2006 systematic review of 13 studies determined that the summary 
relative risk of developing resistance was 1.45, but the results were not significant (Balcells, 
Thomas, Godfrey-Faussett, & Grant, 2006).  A recent review on treatment of LTBI summarizes 
the current expert opinion, stating that due to “limited reports of INH resistance in cases 
occurring after prophylaxis,” and the prevailing understanding of LTBI as a slow growing, 
paucibacillary infection, the probability of spontaneous mutations conferring resistance is very 
low (Vernon, 2013, p. 76).  The main concern with regards to treatment of LTBI and resistance 
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is the treatment of individuals with active TB disease that is not recognized.  This is especially 
problematic in children, due to the difficulties diagnosing active disease. 
 Current recommendations.   
Typically, the recommendation in the USA is for nine months of self-administered 
isoniazid, or, if twelve years old or greater, twelve weekly directly observed doses of rifapentine 
and isoniazid (Centers for Disease Control and Prevention [CDC], 2011).  In low- and middle-
income countries, including Peru, six months of isoniazid monotherapy is the standard practice 
(Estrategia Sanitaria Nacional de Prevencion y Control de la Tuberculosis et al., 2006). 
 Alternative regimens.   
Various shortened and combined regimens to treat LTBI have been studied (LoBue & 
Menzies, 2010; Martinson et al., 2011; van Zyl et al., 2006).  One of the most commonly cited is 
a once weekly isoniazid/rifampicin combination administered for three months (Balcells et al., 
2006; Bright-Thomas, Nandwani, Smith, Morris, & Ormerod, 2010).  Additionally, intermittent 
directly observed twice weekly treatment with either isoniazid or a rifamycin group agent, has 
been tried with high adherence rates (Cruz & Starke, 2013; Vernon, 2013).  A twelve-dose once 
weekly directly observed regimen with rifapentine and isoniazid combined was also shown to be 
highly effective (100% adherence in trial group) (LoBue & Menzies, 2010; Martinson et al., 
2011; Sterling et al., 2011; van Zyl et al., 2006).  Officially, in the USA and Canada, rifamycin 
group agent monotherapy for four months is considered an acceptable alternative treatment, 
while a combination isoniazid/rifampicin regimen is acceptable in the United Kingdom (Leung, 
Rieder, Lange, & Yew, 2011). 
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Treatment of close contacts of mono-resistant, MDR and XDR TB cases.   
 Early on clinicians noticed that M. tuberculosis would develop resistance to streptomycin 
therapy, a problem which continued with the development of new drugs (Keshavjee & Farmer, 
2013).  The problem was exacerbated by incomplete treatment9 and continued to expand until the 
end of the 20th century, when multiple-drug resistant (MDR) TB10 was recognized as a real threat 
arising from improperly administered TB therapy.  This was thanks in part to the MDR TB 
outbreaks in the USA of the late 1980s and early 1990s (CDC, 2010).  The CDC and the WHO 
reported extensively drug resistant (XDR) TB11 as a threat in March of 2006. 
 Common sense would dictate that LTBI contracted from an MDR or XDR TB patient 
would also be resistant to at least isoniazid and rifampin.  Unfortunately, to date no acceptable 
study has confirmed this, or determined what a suitable treatment might be.  In general, 
recommendations for MDR LTBI are to monitor clinically, and possibly treat high-risk contacts 
with combined regimens containing agents active against the resistant strain (CDC/ATS/IDSA, 
2000).  In the 2000 revision of the joint CDC, American Thoracic Society, and Infectious 
Diseases Society of America guidelines, a two-month combined regimen of rifampin and 
pyrazinamide, or a four-month regimen of rifampin was recommended for treatment of a 
suspected isoniazid mono-resistant LTBI ( CDC/ATS/IDSA, 2000). 
                                                 
9 DOTS is the five component WHO recommended TB treatment strategy.  Initially it was focused on 
treating drug susceptible TB only, and was often misapplied, and has therefore been implicated in the rise 
of MDR TB.  For more details see pathogenesis section below and Smith Nonini’s excellent account of 
MDR TB in Peru (Smith-Nonini, 2005). 
10 MDR TB is TB that is resistant to at least isoniazid and rifampicin, the two most powerful first line 
drugs used to treat the disease.  For more information see the excellent chapter on the subject in 
Challenges in Infectious Diseases by Ignatius Fong (Fong, 2013). 
11 XDR TB is TB that is resistant to isoniazid, rifampicin, at least one member of the quinolone family 
and at least one of the following second-line drugs: amikacin, kanamycin, or capreomycin (World Health 
Organization [WHO], 2007). 
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Latent Tuberculosis Infection Treatment Uptake and Adherence 
 There is still much discussion over the cost effectiveness of LTBI treatment, and few 
low- and middle-income countries have followed Peru’s lead in broadening the target population.  
A reason cited for not expanding use of LBTI therapy is low uptake and adherence, which has 
been demonstrated globally, and which further decreases cost-effectiveness.  It can be seen that 
higher-income countries with lower prevalence of LTBI generally have higher adherence rates, 
but even in the best of cases, rates often are not above 50%. 
 South Africa.   
Van Zyl et al. (2006) found low completion rates in children who were close contacts of 
individuals with pulmonary TB in South Africa, showing that completion of a six month 
isoniazid regimen was only 28%, compared to 67% completion of a three month regimen of 
combined isoniazid and rifampicin.  In a similar study in Cape Town, South Africa, Marais et al. 
(2006) found that only 20% of children completed at least five months of isoniazid monotherapy 
for LTBI.  A mixed methods study of LTBI treatment for HIV positive patients in South Africa 
demonstrated that 47% of patients starting a six-month course of LTBI treatment completed it 
(Rowe et al., 2005). 
 Eastern Africa.   
In 2006, a study of TB patients in Malawi evaluated attendance at a hospital-based 
screening service for child contacts.  Only 7.7% of 1438 adult source cases brought their child 
contacts to the clinic, and uptake was significantly lower for male (4.5%) vs. female (12%) 
patients (Nyirenda, Sinfield, Haves, Molyneux, & Graham, 2006).  A study comparing passive 
and active LTBI case finding in Malawi in 2003, found that uptake of treatment was 17% and 
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22% respectively, with economics being cited as the main reason for not starting (Zachariah et 
al., 2003). 
 Pacific Islands.   
A study in Indonesia showed overall good adherence rates (greater than or equal to four 
months of isoniazid) for only 25.6% (95% CI 16.6–36.4) (Rutherford et al., 2012).  
 Middle East.   
A recent study in Iran demonstrated very high completion rates in children less than six 
years old (87% uptake and 100% completion), but had a very low sample size (n=15) 
(Aminzadeh & Asl, 2011).  In a very large study of child contacts in Israel, only 28% of eligible 
contacts started treatment, and only 16% finished (Bibi et al., 2002). 
 USA.   
In a US study from 2002, 89% of persons recommended to start treatment did, and 51% 
completed six months of treatment; however, 20% of those treated underwent directly observed 
therapy, which may have skewed the results considering that directly observed treatment for 
LTBI is not standard practice (Reichler et al., 2002).  In a large study in New York City from 
2002-2004, a total of 15,035 patients started and 6788 (45.2%) completed treatment for LTBI 
(Li, Munsiff, Tarantino, & Dorsinville, 2010).  A large systematic review of LTBI treatment 
adherence in the USA and Canada, published in 2008, showed adherence rates ranging from 19% 
to 96% but noted that overall adherence in high risk groups was low (Hirsch-Moverman, 
Daftary, Franks, & Colson, 2008). 
 South America.   
A study in Lima, Peru highlighted variable adherence rates depending on whether WHO 
definitions (i.e. missed doses are acceptable), or the research site’s more stringent 
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recommendations were used: 53% and 19% respectively (Salazar-López, Arévalo-Abanto, & 
Ticona-Chávez, 2010).  Published abstracts of results from Callao, Peru have shown very low 
completion rates of 12% and 22% in two different studies (Iberico et al., 2011a; Iberico et al., 
2011b). 
Risk Factors for Non-Adherence to LTBI Treatment 
 The majority of research on risk factors has been completed in the USA and Canada.  
Some studies have also been completed in high HIV and TB incidence areas such as Brazil and 
South Africa.  Only one applicable study was found in Peru.  This may have been due to 
limitations in indexing of Latin American journals, but more likely reflects a limited quantity of 
research having been done on the subject.  Additionally, most studies are retrospective. 
 Age.   
The only significant factor associated with low adherence in a Peruvian study at the 
national hospital Dos de Mayo was age; patients over forty years of age had lower adherence to 
treatment (Salazar-López et al., 2010).  Another study in New York City showed decreased 
adherence in adults older than thirty-five (Li et al., 2010).  A study specifically targeting Latino 
adolescents in San Diego showed worse adherence in older adolescents, with age analyzed as a 
continuous independent variable in the range of twelve to nineteen years (Hovell et al., 2003b).  
A study in Brazil showed no significant relationship between any age group and adherence 
(Machado et al., 2009).  One paper noted that studies on age and its relationship to LTBI 
treatment adherence have shown variable results, and there is ambiguity about what age means 
(Goswami et al., 2012).  A large retrospective survey of LTBI treatment in the USA and Canada 
showed age greater than fifteen to be significantly associated with failure to complete treatment 
(Horsburgh et al., 2010). 
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 Gender.   
In most reviewed studies gender was not significantly related to uptake, or completion of 
treatment (Rutherford et al., 2012; Salazar-López et al., 2010; Sebastian & Bothamley, 2000; 
Trajman et al., 2010).  A prospective study in the late 1990s in Indonesia did show females to be 
three times as likely to be highly adherent to treatment for LTBI (Ngamvithayapong, 
Uthaivoravit, Yanai, Akarasewi, & Sawanpanyalert, 1997). 
 Ethnicity/race/place of origin.   
A large multicenter study of risk factors for completion of LTBI treatment in Canada, 
Saudi Arabia and Brazil showed that patients in Brazil had overall lower completion rates.  The 
authors are undertaking studies on health beliefs, culture, and socioeconomic factors to further 
explore this finding (Trajman et al., 2010).  Studies in the USA, have consistently shown that 
non-US born persons have higher completion rates (LoBue & Moser, 2003; Parsyan, Saukkonen, 
Barry, Sharnprapai, & Horsburgh, 2007). 
 Costs/poverty.   
A study in Indonesia identified high transport costs and medication costs as significantly 
associated with poor adherence (Rutherford et al., 2012).  A study in Brazil showed that close 
contacts needing to take more than one bus to the health center were much less likely to 
complete treatment, and that bus fares represented a significant cost to the low-income families 
involved in the study (Machado et al., 2009).  A lower education level has been associated with 
decreased adherence in Hispanics in the United States (Zuñiga, 2012).  Unstable housing is 
another related factor (Hirsch-Moverman et al., 2008).  The quantitative portion of a mixed 
methods study of children taking LTBI treatment in Indonesia reported that, from an extensive 
list of possible risk factors, only cost of transportation and cost of medications had a significant 
FACTORS AFFECTING LATENT TUBERCULOSIS TREATMENT 
 
30
correlation with low adherence rates (Rutherford et al., 2012).  The qualitative portion of the 
same study demonstrated a preponderance of cost-related themes related to adherence 
(Rutherford et al., 2012). 
 Index case related factors.   
A study in southeast Asia found that TB patient index cases with high perceived 
susceptibility to TB disease were three times as likely to bring in their close contacts aged less 
than fifteen in for evaluation, but found no significant relationship to age, education, 
socioeconomic status, or relationship to index case (Tornee et al., 2005).  Additionally, TB 
patients with high stated intention and who resided near the health center were more likely to 
bring their close contacts in for evaluation (Tornee et al., 2005).  These data are important 
because screening is the first step towards uptake of LTBI treatment. 
 Duration of treatment.   
Generally, shorter regimens and directly observed treatment regimens have high 
completion rates.  The Trajan et al. (2010) multicenter study of risk factors considered a shorter 
regimen the strongest indicator for completion. 
 Other factors.   
The Trajman et al. 2010 study also found that “early adherence, measured by regularity 
of treatment and percentage of doses taken, was predictive of final completion of treatment” (p. 
557).  Side effects of medication used in LTBI treatment was cited as a significant determinant 
of non-completion in a study in Brazil (Machado et al., 2009).  A study of Latino adolescents in 
San Diego considered engagement in risky behavior as a negative predictor of adherence (Hovell, 
et al., 2003a).  In a study of risk factors in primarily foreign born persons (19% African, 20% 
Latin American) with LTBI living in the USA, factors positively correlated to completion 
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included being a close contact to an infectious TB case (RR 2.5), and having regular primary 
care (RR 1.4) (Goswami et al., 2012).  Goswami et al. (2012) also categorized people with LTBI 
into risk categories and demonstrated that higher risk for progression of TB disease was 
correlated with a higher likelihood of treatment uptake, but not completion. 
 Operational factors have also been cited in the literature.  One study in HIV positive 
individuals in South Africa highlighted that misunderstanding of how to diagnose LTBI and the 
importance of treating LTBI contributed to an uptake of zero because no patients were even 
aware that LTBI treatment was an option (Lester et al., 2010). 
Tuberculosis Infection and Disease in Urban Peru 
Demographics and geography. 
 Peru is a developing country with one of the strongest economic growth rates in South 
America, ranking third in terms of real GDP growth rate.  The World Bank (n.d.) rates Peru as an 
upper middle-income country and reported the GNI per capita in Peru was 4,710 USD in 2010, 
increasing to 5,150 USD in 2011.  Despite a strong economy, the country continues to have high 
rates of rural poverty and disparities between poor and rich in more developed urban settings 
such as the capital city of Lima.  In 2010, 12.7% of the population lived on less than 2 
international dollars per day, adjusted for purchasing power parity (PPP), and approximately 
30% lived below the official poverty line (World Bank, n.d.) (Table 4). 
The 2007 Peruvian census placed the national population at 28.5 million people (Instituto 
Nacional de Estadistica e Informatica [INEI], n.d.) and a later document, by the Dirección 
Tecnica de Demografía e Indicadores Sociales of the INEI of Peru, in conjunction with the 
United Nations (UN), estimated that in 2012 the population would have grown to 30.1 million 
people (2009) (Table 4). 
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Table 4  
Social Demographics 
 
  
Characteristic 2007 (last census) 2012 
Total population, Peru * 28,481,901 30,135,875 †† 
Population in Lima Metropolitan Area * 8,482,619 10,364,319 †† 
Population in Ventanilla * 280,511 370,517 †† 
Uninsured (public or private) in Peru ** 15,813,459 (56%) - 
Uninsured in Ventanilla (2007) ** 167,101 (60%) - 
Average life expectancy, national ** 69 - 
Infant mortality rate, national 31/1,000 live births ** 14/1,000 live births †† 
Gross national index per capita, PPP  † $7,160 $9,440 †† 
Population under national poverty line1 † 42.4% 27.8% †† 
Tuberculosis incidence, national ** 108/100,000 - 
Note: Chart modified from Shin et al., 2008; PPP=purchasing power parity1 
*(Instituto Nacional de Estadistica e Informatica [INEI], 2009) 
**(Instituto Nacional de Estadistica e Informatica, n.d.) 
† World Bank, n.d. 
†† 2011 World Bank projection 
 Geographically, Peru is comprised of 25 administrative regions, each of which contains 
various provinces divided into districts.  Lima, the capital city, comprises a district in the 
province of Lima.  Despite this geographical distinction, politically the city of Lima is 
considered to comprise the entire province of Lima, which functions autonomously from the 
larger Lima regional government due to its status as national capital.  Additionally, the province 
of Lima completely surrounds the costal region of Callao, which is made up entirely of the 
Constitutional Province of Callao and considered part of the Lima greater metropolitan area.  
The Lima metropolitan area is a densely populated area with about 30% of the country’s 
population, while the city of Lima occupies less than 0.5% of the total land area of the country 
(INEI, n.d.). 
 Ventanilla (see Appendix C for images) is the largest human ‘asentamiento,’ or squatter 
settlement, in Peru with an INEI estimated population of about 0.4 million people in 2012 (Table 
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4).  Ventanilla is comprised of Peruvians who have migrated from the mountains (sierra) and the 
jungle (selva) and other poor rural areas looking for a better life in Lima.  Its population features 
a mix of income levels, but the majority of its inhabitants are below the national poverty line.  
About 5% of the population of Ventanilla lives in improvised shacks or is squatting on land that 
is not meant for human settlement.  About 93% live in sturdier independent dwellings, often 
made of recycled wood walls with corrugated roofs, and another 2% of the population live in 
more permanent apartment buildings (e.g. cement or cinder block), connected housing, or other 
accommodations (INEI, n.d.) (Figure 2). 
Figure 2. Housing type in Ventanilla in 2007 (INEI, n.d.) 
 
Tuberculosis control program. 
 The Peruvian ministry of health operates sixteen TB program offices, which diagnose and 
manage care for affected individuals and families in the district of Ventanilla.  Officially, the 
sixteen offices are part of the Ventanilla health network.  Fifteen are housed in Ministry of 
FACTORS AFFECTING LATENT TUBERCULOSIS TREATMENT 
 
34
Health centers and one is in a hospital, which is an independent collaborator with the Ministry of 
Health. 
 All centers rely primarily on passive case finding.  The Ministry of Health uses public 
health education campaigns, a web site, public service announcements and posters in the health 
centers and hospital to encourage all individuals experiencing more than two weeks of coughing 
to go to the health center and submit sputum samples for smear microscopy.  If diagnosed with 
TB, patients are asked to list their close contacts irrespective of whether they live in the same 
house. 
 The TB control program in Peru is called The National Sanitary Strategy for the 
Prevention and Control of Tuberculosis, or Estrategia Sanitaria Nacional de Prevención y 
Control de la Tuberculosis (ESN-PCT).  In the 1990s the WHO considered Peru’s program a 
model program for DOTS because of high treatment rates and early adoption.  The Peruvian 
strategy is more inclusive that other plans in the region, such as Chile and Ecuador, and its 
consideration of social determinants is unmatched.  Since 1991, the Ministry of Health has 
indicated that contacts younger than fifteen should be evaluated for active TB and, in its absence, 
be administered six months of LTBI treatment.  In April 2006, the policy was updated to include 
contacts up to nineteen years old (Estrategia Sanitaria Nacional de Prevencion y Control de la 
Tuberculosis et al., 2006).  Additionally, contacts are advised to seek consultation if they 
experience cough of more than two weeks, and/or fever and night sweats.  The policy also gives 
physicians wide latitude in decision making, and allows administration of LTBI outside of the 
recommendations for a series of conditions that may make an adult immune compromised 
(Estrategia Sanitaria Nacional de Prevencion y Control de la Tuberculosis et al., 2006).  These 
elements make it the most inclusive LTBI treatment strategy in South America. 
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 Latent tuberculosis infection control.   
Despite the existence of a model TB program that goes beyond international guidelines, 
there is low uptake of, and adherence to, LTBI treatment in Peru.  The Peruvian government 
indicates in their national tuberculosis program policy that LTBI treatment should be given to all 
contacts less than twenty years old who do not have active TB (Estrategia Sanitaria Nacional de 
Prevencion y Control de la Tuberculosis et al., 2006).  Before isoniazid is prescribed, however, 
contacts must complete medical assessments.  This requires questioning by health center nurse, 
identification by index case, and several health center visits, which are free for those with social 
security, but may involve costs for the uninsured and always involve indirect costs such as 
transport.  All these may be barriers for poor families (See Appendix A for flow-chart of 
process).   
 The ISIAT project (Rocha et al., 2011) studied the equity of adherence between Peruvian 
families with income in the bottom quartile and families with income in the top quartile of their 
sample population, and showed that despite the increased equity and increased completion, the 
rates of completion were still very low across the board (Iberico et al., 2011a).   
The importance of LTBI treatment, coupled with the poor levels of uptake and 
completion globally and in Peru, prompted this study’s examination of factors affecting uptake 
and completion, derived from information contained in index case treatment cards. 
 Other than the studies done by the ISIAT group, little to no research has been done on 
factors affecting uptake of, and adherence to, LTBI treatment in Peru.  Globally there has been 
some research, but only a small amount of it has been done on LTBI treatment for HIV negative 
individuals. 
  
FACTORS AFFECTING LATENT TUBERCULOSIS TREATMENT 
 
36
Description of Innovative Socio-economic Interventions Against Tuberculosis 
 In 2007 a research project began in Ventanilla, a district of the Peruvian city Callao 
(Figure 3) to investigate the impact of socioeconomic interventions on TB control.  The project 
was called: Innovative Socio-economic Interventions Against Tuberculosis (ISIAT).  The 
research team for ISIAT works in conjunction with Innovation for Health and Development 
(IFHAD, a British non-governmental organization (NGO)), PRISMA (a Peruvian NGO), and the 
Peruvian Ministry of Health. 
 
Figure 3. Map of Lima and Callao 
Large oval denotes Ventanilla. Insert depicts larger Lima Metropolitan Area. 
Modified from Callao District in Wikipedia, n.d., Retrieved September 12, 2009, from http:// 
http://en.wikipedia.org/wiki/Callao_District. Licensed under the Creative Commons Attribution-Share 
Alike 3.0 Unported license. 
 
 Despite a focused biomedical approach to controlling TB via DOTS, recurrence and 
transmission of the disease continues in the shantytowns where the research is occurring to a 
greater degree than in the country as a whole (Figure 4).  As a response, the ISIAT project takes 
a three-pronged biosocial approach to controlling TB: rights (education & advocacy), social 
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interventions (microcredit, training, and microenterprise activities), and biomedical interventions 
(development and implementation of appropriate sustainable diagnostics).  Social interventions 
target poverty, while the rights approach leads to improved TB care via improved case-finding, 
prophylactic treatment of close contacts, and better adherence to treatment.  The social aspects of 
ISIAT make it unique.  This biosocial approach has already shown promising results in leading 
to an increase of pediatric TB diagnosis (Rocha et al., 2011). 
Figure 4. Tuberculosis incidence per 100,000 people in Peru 
Peru starts DOTS in 1990 and achieves increased case finding in 1991. ISIAT begins in 2007. 
Peru data is from the Instituto Nacional de Estadistica e Información (INEI). 
Ventanilla data is from an unpublished dataset incorporating INEI census data. 
 
The ISIAT study has so far been described in one operational assessment done in 2011 
(Rocha et al., 2011).  The study was designed to evaluate a group of socio-economic 
interventions for the impact they might have on strengthening TB control.  Specifically, the study 
aimed to measure uptake of TB care and prevention services, as defined in Peruvian health 
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policy, in interventions and monitoring (control) groups made up of randomly allocated health 
centers.  The TB care and prevention services included LTBI treatment. 
 Before beginning the intervention, the ISIAT team identified barriers to TB control by 
interviewing TB-affected families using both quantitative and qualitative methodology (Onifade 
et al., 2010).  Data from previous studies utilizing randomly selected population control 
households, which had been collected starting in 2003, were also used.  Based on these findings, 
knowledge of the literature, and contextual knowledge, the ISIAT team then offered four 
categories of activities to reduce these barriers: (1) household visits (health knowledge and 
gender rights) (2) community workshops (community mobilization and advocacy), (3) 
psychosocial support (community mobilization, advocacy, recruitment, and continued 
participation), (4) microenterprise, microcredit, vocational training, food transfers, and cash 
transfers (poverty mitigation and income generation).  Categories one through three were 
intended to affect health seeking, time to diagnosis, contact screening, treatment uptake (TB and 
LTBI), treatment completion (TB and LTBI), sustained cure, and prevention behaviors.  
Category four was intended to directly combat poverty, with the aim of indirectly affecting 
poverty-associated risk factors.  These factors included housing quality, crowding, and nutrition; 
all of which can affect the spread of LTBI and incidence of TB disease.  This last category 
included vocational training in animal husbandry and other productive activities, loans for 
startup costs of a business, and food and cash transfers tied to TB control goals, such as attending 
DOTS. 
 Built in to all of the interventions were ‘crosscutting outputs,’ i.e. outputs that were 
designed to affect both poverty (i.e. fundamental determinants of health) and health promotion, 
in a more traditional public health sense.  The main interventions falling under this definition 
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were: (a) empowerment (mostly category 2, as discussed above, as well as daily encouragement 
and facilitation of any empowerment activities undertaken by TB affected families), (b) 
advocacy (research team members actively attempting to influence health care policies), and (c) 
equity (purposeful targeting of the poorest and most vulnerable members of the intervention 
group). 
 The monitoring group received the standard of care provided by the health system as well 
as some educational benefit from the visit of ISIAT team members in an initial interview when 
the index case was identified.  Due to ethical concerns, community workers were not given any 
specific indications on withholding information on TB treatment, LTBI treatment, and/or health 
rights, or from helping families find requested information. 
Methods 
  For this study of LTBI treatment in Ventanilla, a quantitative descriptive analysis of TB 
treatment data was conducted.  The purpose of this study was to identify factors that were 
associated with high or low adherence with LTBI treatment by children and adolescents. 
Study Cohort 
 The cohort in this study was identified through health center registries of TB-affected 
families in the health network of Ventanilla, Peru.  Most index cases were discovered via passive 
case finding, some were found in active case finding campaigns by the TB program, or through 
contact evaluation.  Aggregate data were available for all child contacts listed on a TB patient’s 
treatment card (see Appendix B for example) by age group.  The data were de-aggregated using 
Stata®11 (StataCorp, LP, College Station, TX, USA), which involved creating new rows of data 
representing individual contacts registered on the index case treatment card.  All data in new 
rows were duplicated from the household, or index case data, except the data on LTBI treatment.  
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Dummy variables were created indicating age range and number of months of treatment 
completed for each contact listed.  Three and four weeks of treatment dispensed were considered 
one month of LTBI treatment for the purposes of this study. 
The unit of analysis was individual contacts.  Inclusion criteria were treatment cards of 
TB cases indicating TB treatment between June 1st 2006 and Dec 31st 2010 in one of 16 
catchment areas in Ventanilla.  Cases could not be MDR and had to have at least one registered 
contact younger than twenty years old.  This date range was chosen because the TB control 
policy changed in April 2006 to include adolescents from the ages of fifteen to nineteen in the 
LTBI treatment recommendations.  This gave a leeway of three months for health centers to 
adopt the new policy.  December 2010 was the last date for which the dataset contained reliable 
information.  The data had been previously collected for an ongoing project dating back to 2002 
by the NGOs: Innovations For Health And Development (IFHAD) and Asociación Benéfica 
Prism (PRISMA) in conjunction with the Universidad Peruana Cayetano Heredia (UPCH).  IRB 
approval was obtained through Wright State University (Appendix D). 
Data Collection 
 For this study TB patients were referred to as index cases.  All contacts identified by the 
index case at time of registration at the health center, and/or at time of domiciliary visit by health 
center staff, were called close contacts.  If a household had more than one case of TB disease, the 
first case was denoted the index case and subsequent cases were considered secondary cases.  
For the purposes of this paper, all cases of TB disease with contacts were considered index cases, 
unless otherwise noted (see methods section for more explanation). 
 LTBI treatment prescription records were generated prospectively at the point of patient 
care by health center staff, at the time of patient registration.  Records were de-identified and 
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digitized prospectively by the IFHAD research team as they were generated, and previous to this 
author’s arrival.  The research team also prospectively visited all the households and enrolled 
them in the IFHAD study in order to register demographic information, socioeconomic 
information and other variables for ongoing studies.  Specific variables used for this study from 
the treatment card were: date of first pill of TB treatment taken by the index patient, number of 
contacts listed on the treatment card by age grouping (0-14 and 15-19), number of contacts 
completing each month of treatment by age grouping, and status of treated patient (completed 
treatment, cured, abandoned treatment, etc.).  This information was analyzed with ISIAT study 
variables: date intervened in IFHAD study, study group (monitoring or intervention), monthly 
income of household, census of contacts, level of education of patient, patient drug use, time 
household had been living in Ventanilla and geographic place of birth (sierra, jungle, Lima, or 
the coast other than Lima).  Contacts who were lost to follow up during treatment were 
reclassified as having abandoned treatment, and the number of weeks of LTBI treatment 
dispensed were recorded and included in the analysis. 
Variable Selection 
 Due to the enormity of data present on the TB treatment cards and household surveys, 
and the limited scope of the research questions being addressed, key variables were chosen for 
analysis.  These variables best aligned with previously studied adherence factors, and with the 
research team’s understanding of the context of Ventanilla and LTBI treatment (See Table 5).  
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Table 5  
Variables 
 
Variable Operational Definition 
Range of Possible 
Scores/Coding 
Type of Variable 
Independent variables    
Contact characteristics 
Age range 
Contact’s age range as present in 
de-identified dataset 
0-15 = 0 
16-21 =1 
categorical 
Is a close contact of a 
secondary case 
Whether individual is a close 
contact of an index case in a 
household or a secondary case 
yes =1 
no = 0 
categorical 
Experimental group 
 
Whether individual was 
registered on a card from an 
intervened or a monitoring 
household 
monitoring = 1 
intervention = 0 
categorical 
Index case characteristics 
Education completed 
high school 
Whether, or not index case had 
completed high school, if 
appropriate. 
yes =1 
no = 0 
categorical 
Place of birth Place of birth 
Ventanilla = 1 
other Lima Metro = 2 
coast = 3 
central Highlands = 4 
jungle = 5 
categorical 
Drug use Any illicit drug use by index case 
yes =1 
no = 0 
categorical 
Abandoned DOTS 
Treatment card abandoned status 
vs. finished, or cured 
yes =1 
no = 0 
categorical 
Time lived in Lima 
 
Time lived in Lima Metropolitan 
Area necessary to be well settled 
<2 years = 1 
≥2 years = 0 
categorical 
Poverty proxies/household characteristics 
Crowding 
≥ 75th percentile crowding, which 
was nine persons 
crowded = 1 
less crowded = 0 
categorical 
Income per person 
Two income groups were defined 
using below the median as lower-
income group 
lower-income = 1 
higher-income = 0 
categorical 
Dependent variables    
LTBI treatment uptake 
Whether or not contact was 
dispensed any LTBI treatment 
doses 
<2 weeks = 1 
≥2 weeks = 0 
categorical 
LTBI treatment 
adherence 
Whether or not there was poor 
adherence to LTBI treatment or 
good adherence 
<22 weeks = 1 
≥22 weeks = 0 
categorical 
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Analyses 
The research questions considered in this study concerned factors contributing to LTBI 
treatment uptake and adherence and whether or not ISIAT improved uptake and adherence of 
LTBI treatment. 
 Two separate analyses were done.  First, a descriptive analysis utilized treatment card 
data linked to households in the ISIAT monitoring group.  This analysis examined uptake and 
completion of LTBI treatment to answer the first research question.  The second analysis 
compared uptake and completion of LTBI treatment between the interventions and monitoring 
groups of ISIAT in order to answer the second research question.  An additional sub-analysis of 
LTBI uptake and adherence among contacts of secondary cases enrolled in this cluster 
randomized controlled trial was part of this second analysis. 
 Data were analyzed in Stata®.  Treatment card data were merged with IFHAD study data 
using unique identifiers for each household and treatment card.  Aggregate data for LTBI 
treatment adherence were then expanded, based on the number of contacts listed on the card by 
age group.  This enabled the unit of analysis to be individuals clustered in households.  Simple 2 
x 2 tables were made for all binomial variables, and relative risks were calculated.  Dichotomous 
variables were created from continuous variables using the median as an arbitrary cutoff rate, 
except in some special instances where the literature suggested different cutoff points, which are 
discussed in more detail below.  Significance was evaluated with Fisher’s exact test.  The alpha 
level was 0.05, and p-values from 2-tailed tests less than or equal to this value were considered 
to be unlikely to be explained by chance. 
 In order to simplify the analysis, several variables were converted from continuous or 
categorical to binomial.  Income per person was used as the primary socioeconomic indicator 
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and was defined by median income.  For crowding, 75th percentile (9 persons in a household) 
and above was used as the cutoff point, as this has been shown to be a more strongly associated 
with TB disease than using the median as a cutoff point (Boccia et al., 2009).  Length of 
residence in the Lima metro area was used as an indicator of how established a household was 
likely to be within their community, and was also included with the idea that more established 
households would have more community support and more knowledge about services available.  
The median time (seven years) seemed to be too high to differentiate established households vs. 
less established households; therefore a more intuitive cutoff of two years was arbitrarily 
selected and used in all analyses.  Income was converted to US dollars using an exchange rate of 
2.85 PEN12 = 1 USD. 
 For all analyses, two dependent variables were considered: LTBI treatment uptake and 
good adherence.  Medication for contacts was dispensed weekly to index cases during DOTS.  
The LTBI treatment data were originally recorded in a weekly format by health center staff on 
the treatment cards; in the ISIAT database, however, the data were reported in a monthly format, 
where a month was defined as two or more weeks of treatment.  Thus one week of treatment was 
counted as zero months, two to five weeks were counted as one month, six to nine weeks as two 
months, and so on.  Practically this meant that, for this study, uptake was defined as treatment 
dispensed to a child contact for at least two weeks, and good adherence was defined as 22 or 
more weeks of treatment dispensed.   
Results 
 For the study period, there were 2427 index and secondary TB patient cases in the 
IFHAD database.  Of these, 110 had missing treatment cards, 170 received MDR-TB treatment, 
                                                 
12 PEN = Peruvian Nuevo Sol, the unit of currency in Peru. 
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and 642 had no contacts younger than 20 years old so were excluded.  The remaining 1505 
treatment cards were utilized in this study.  
Descriptive Results for the Entire Study Population 
 There were 1267 treatment cards including 3226 contacts in the monitoring group in the 
ISIAT study.  There were 238 treatment cards including 617 contacts in the interventions group.  
Participants in the monitoring and interventions groups had similar baseline characteristics for 
the independent variables studied (See Table 6).   
Descriptive Results for the Monitoring (Control) Group 
This section presents analysis of the data for the monitoring group only; this was done so 
as to eliminate any effect the intervention may have had on the population.  Of the close 
contacts, 1102 (34.2%, 95% CI [32.5, 35.8]) initiated treatment for LTBI and 378 (11.7%, 
95%CI [10.6, 12.8]) had good adherence.  Most of the close contacts (77.5%) were older than 
fourteen years old.  The median per capita income was equivalent to 1.12 USD (inter-quartile 
range 1.90 to 4.94) per day and assuming 30 days to a month.  The median number of household 
residents was 7 (inter-quartile range 5 to 9).  The proportion of contacts residing in lower-income 
houses (below the median) was 48.7%, and the proportion of contacts residing in crowded 
houses (25th percentile) was 29.7%.  Close contacts of secondary cases were the minority at 7.5% 
of all contacts. 
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Table 6  
Descriptive Variables by Monitoring and Intervention Groups 
 
Characteristic 
INDEPENDENT 
Monitoring 
n (%) 
Intervened 
n (%) 
Total 
n (%) 
Age (years)    
 15-19  2500 (77.5) 481 (78) 2981 (77.6) 
 0-14 726 (22.5) 136 (22) 862 (22.4) 
Lower-income    
 yes 1222 (48.7) 312 (52.4) 1534 (49.4) 
 no 1287 (51.3) 283 (47.6) 1570 (50.6) 
Crowded    
 no 2267 (70.3) 404 (65.5) 2671 (69.5) 
 yes 959 (29.7) 213 (34.5) 1,172 (30.5) 
Education past high school    
 no 1466 (55.9) 351 (58.4) 1817 (69.1) 
 yes 1156 (44.1) 250 (41.6) 1406 (30.9) 
Index case place of birth    
 Ventanilla 120 (5.8) 27 (4.5) 147 (5.5) 
 Other Lima Metro Area 899 (43.7) 229 (38.5) 1128 (42.6) 
 Coast 268 (13.0) 77 (12.9) 345 (13.0) 
 Central 597 (29.1) 167 (28.1) 764 (28.8) 
 Jungle 171 (8.3) 95 (16.0) 266 (10.0) 
Index case drug use    
 Yes 196 (6.1) 31 (5.0) 227 (5.9) 
 No 3030 (93.9) 586 (95) 3616 (94.1) 
Index case abandoned DOTS    
 Yes 379 (14.3) 53 (11.3) 432 (13.9) 
 No 2272 (85.7) 414 (88.7) 2686 (86.1) 
Index case time in Lima    
 <2 years 737 (36.4) 224 (38.1) 961 (36.8) 
 ≥2 years 1289 (63.6) 364 (61.9) 1653 (63.2) 
Is close contact of a 
secondary case 
   
 yes 229 (7.5) 26 (4.5) 255 (7.0) 
 no 2833 (92.5) 558 (95.5) 3391 (93.0) 
DEPENDENT    
LTBI treatment uptake    
 <2 weeks 2124 (65.84) 251 (40.68) 2375 (61.8) 
 ≥2 weeks 1102 (34.16) 366 (59.32) 1468 (38.2) 
Adherence to LTBI    
 <22 weeks 2848 (88.3) 426 (69.0) 3274 (85.2) 
 ≥22 weeks 378 (11.7) 191 (31.0) 569 (14.8) 
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 Considering index case factors, 44.1% were educated at least to the high school, or 
appropriate level.  Although 49.5% had been born in Lima Metropolitan Area, only 5.8% had 
been born in Ventanilla.  Sixty three percent of index cases had resided in Lima for more than 
two years.  Among index cases, 6.1% admitted to having used some illicit substance in the past, 
and 14.3% were noted to have abandoned their course of DOTS before completion. 
Risk Factor Analysis for the Monitoring (Control) Group 
 Uptake.   
Fisher tests for non-uptake of LTBI treatment (Table 7) showed that close contacts in the 
fifteen-to-nineteen year old age group were more likely to fail to initiate treatment (RR 1.29, 
95% CI [1.23, 1.35], p<0.001).  Close contacts living in a lower-income household (RR 1.06, 
95% CI [1.00, 1.13], p=0.05), or in a crowded household (RR 1.10, 95% CI [1.04, 1.16], 
p=0.003) were slightly more likely to fail to initiate treatment than those living in a less crowded 
household.  Birthplace of index cases was in some cases correlated with failing to initiate 
treatment; those contacts associated with index cases who had been born in any district of Lima 
or Callao (except Ventanilla) had an increased risk of failing to initiate treatment (RR 1.08, 95% 
CI [1.01, 1.15], p=0.04).  Having an index case born in the central highlands of Peru was a 
protective factor for uptake (RR 0.86, 95% CI [0.79, 0.93], p<0.001).  If the index case 
associated with a contact abandoned DOTS, there was an increased risk that the contact would 
fail to initiate treatment (RR 1.34, 95% CI [1.26, 1.42], p<0.001).  Less than two years of a 
family being established in Lima was also associated with a contact failing to initiate treatment 
(RR 1.15, 95% CI [1.08, 1.23], p<0.001).  Finally, there was also an increased risk of failure to 
initiate treatment if the TB-affected individual associated with the contact was considered a 
secondary case (RR 1.16, 95% CI [1.07, 1.25], p<0.001). 
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Table 7  
Risk Factors for Latent Tuberculosis Infection Treatment Uptake and Adherence 
 
Independent 
variables 
No uptake*  
n (%) 
RR [95%CI] p value 
Poor 
adherence** 
n (%) 
RR [95%CI] p value 
Age (years)         
 15-19  579 (79.8) 1.29 1.23-1.35 <0.001 690 (95.0) 1.10 1.08-1.13 <0.001 
 0-14 1545 (61.8) 1   2158 (86.3) 1   
Income †         
 Lower 791 (64.7) 1.06 1.00-1.13 0.052 1078 (88.2) 1.02 0.99-1.05 0.253 
 Higher 784 (60.9) 1   1115 (87.6) 1   
Crowded ††         
 yes 451 (70.9) 1.10 1.04-1.16 0.003 588 (92.5) 1.06 1.03-1.09 <0.001 
 no 1673 (64.6) 1   2260 (87.3) 1   
IC education         
 HS or less 1148 (63.3) 0.97 0.91-1.03 0.336 1574 (86.8) 1.03 1.00-1.06 0.084 
 Past HS 496 (61.3) 1   722 (89.2) 1   
IC place of 
birth 
        
 Ventanilla 83 (69.2) 1.12 0.99-1.27 0.121 104 (86.7) 0.99 0.92-1.07 0.888 
 Other Lima ‡ 583 (64.8) 1.08 1.01-1.15 0.035 827 (92.0) 1.10 1.07-1.14 <0.001 
 Coast 176 (65.7) 1.06 0.97-1.17 0.224 228 (85.1) 0.97 0.92-1.03 0.282 
 Central 333 (55.8) 0.86 0.79-0.93 <0.001 483 (80.9) 0.90 0.86-0.94 <0.001 
 Jungle 104 (60.8) 0.98 0.86-1.11 0.681 149 (87.1) 1.00 0.94-1.06 1.000 
IC drug use         
 Yes 139 (70.9) 1.08 0.99-1.19 0.140 178 (90.8) 1.03 0.98-1.08 0.302 
 No 1985 (65.5) 1   2670 (88.1) 1   
IC abandoned 
DOTS 
        
 Yes 308 (81.3) 1.34 1.26-1.42 <0.001 366 (96.6) 1.13 1.10-1.16 <0.001 
 No 1380 (52.1) 1   1938 (85.3) 1   
IC time in 
Lima 
        
 <2 years 498 (67.6) 1.15 1.08-1.23 <0.001 668 (90.6) 1.07 1.03-1.10 <0.001 
 ≥2 years 757 (58.7) 1   1094 (84.9) 1   
Close contact 
of SC 
        
 yes 173 (75.6) 1.16 1.07-1.25 0.001 197 (86.0) 0.97 0.92-1.03 0.286 
 no 1951 (65.1) 1   2651 (88.5) 1   
Note: CI = confidence interval; HS = high school; IC = index case; LTBI = latent tuberculosis infection; 
RR = relative risk; SC = secondary case  
* No uptake defined as less than two weeks of treatment recorded as dispensed 
** Poor adherence defined as less than 22 weeks of treatment recorded as dispensed 
† Lower-income defines as less than median income per person (33.68 USD per month) 
†† Crowded defined as nine or more people in one household 
‡ Refers to Lima Metropolitan Area, which includes both Callao and Lima 
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 Education level of index case, and any illicit drug use were not significantly associated 
with close contacts failing to initiate treatment.  There was no significant association found if the 
index case related to the close contact had been born in Ventanilla, coastal region or the jungle 
region. 
 Adherence.   
Fisher tests examining poor adherence to LTBI treatment (Table 7) showed that being in 
the fifteen-to-nineteen year old age group was associated with poor adherence (RR 1.10, 95% CI 
[1.08, 1.13], p<0.001).  Close contacts living in a crowded household (RR 1.06, 95% CI [1.03, 
1.09], p<0.001) were more likely to have poor adherence than those living in a less crowded 
household.  Birthplace of index case was also correlated with poor adherence, if birthplace was 
Other Lima Metropolitan (RR 1.10, 95% CI [1.07, 1.14], p<0.001).  If birthplace was central 
highlands, however, contacts were more likely to have good adherence (RR 0.90, 95% CI [0.86, 
0.94], p<0.001).  If the contacts associated with the index case had abandoned DOTS, there was 
an increased rate of poor adherence (RR 1.13, 95% CI [1.10, 1.16], p<0.001).  Finally, if the 
contact’s family had been established in Lima for less than two years, the contact was more 
likely to have poor adherence (RR 1.07, 95% CI [1.03, 1.10], p<0.001). 
 Lower-income, education level of index case, birth place of index case in Ventanilla, 
coast or jungle, any illicit drug use, and being the close contact of a secondary case were not 
significantly associated with poor adherence. 
ISIAT Latent TB Infection Treatment Uptake and Adherence Analysis  
 All contacts uptake.   
Of those in the monitoring group, 34.2% started LTBI treatment, defined as having had 
two or more weeks of treatment dispensed.  In the interventions group, 59.3% of contacts started 
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LTBI treatment.  Contacts in the monitoring group had 1.62 (RR 95% CI [1.47, 1.79], p<0.001) 
times the risk of not starting when compared to the interventions group.  The contacts in the 
interventions group were 1.74 times more likely to start LTBI treatment than those in the 
monitoring group (RR 95% CI [1.60, 1.88], p<0.001) (Table 8).
 
Table 8  
Impact of ISIAT on Uptake and Completion of LTBI Treatment 
 
  
Uptake* 
(%) RR [95%CI] 
Fisher 
p value 
Good 
adherence** 
(%) RR [95%CI] 
Fisher 
p value 
All contacts         
 Intervened 366 (59.3) 1.74 1.60-1.88 <0.001 191 (31.0) 2.64 2.27-3.07 <0.001 
 Monitored 1102 (34.2)    378 (11.7) 1   
Contacts of 
ICs 
        
 Intervened 355 (60.1) 1.72 1.59-1.87 <0.001 190 (32.2) 2.78 2.39-3.25 <0.001 
 Monitored 1046 (34.9) 1   346 (11.5) 1   
Contacts of 
SC 
        
 Intervened 11 (42.3) 1.73 1.05-2.86 0.061 1 (3.85) 0.28 0.04-1.93 0.218 
 Monitored 56 (24.5) 1   32 (14.0) 1   
Note: CI = confidence interval; IC = index case; LTBI = latent tuberculosis infection; RR = relative risk; 
SC = secondary case 
* Uptake defined as greater than or equal to two weeks of treatment recorded as dispensed 
** Good adherence defined as greater than or equal to 22 weeks of treatment recorded as dispensed 
 
 Contacts of index cases uptake.  
The results for this group were nearly identical to the all contacts group, with 65.1% of 
those in monitoring having poor adherence (RR 1.63, 95% CI [1.47, 1.81], p<0.001).  Contacts 
in interventions were 1.74 times more likely to start treatment (95% CI [1.59, 1.87], p<0.001). 
 Contacts of secondary cases uptake.  
The results for this group were non-significant for uptake (RR 1.73, 95% CI [1.05, 2.86], 
p=0.061). 
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 All contacts adherence.   
There were 3226 contacts in the monitoring group and 617 in the interventions group 
included in this study.  Of those in the monitoring group, 11.7% finished LTBI treatment, and 
88.3% had poor adherence, previously defined in the analysis section as less than 22 weeks of 
treatment dispensed.  In the interventions group, 31.0% of contacts finished LTBI treatment, and 
69% had poor adherence.  Contacts in the monitoring group had 1.28 times the risk of having 
poor adherence when compared to the interventions group (95% CI [1.21, 1.35], p<0.001).  
Contacts in interventions were 2.64 times more likely to complete LTBI treatment than those in 
the monitoring group (95% CI [2.27, 3.07], p<0.001). 
 Contacts of index cases adherence.   
When secondary cases were removed from consideration there were 2997 monitoring and 
591 interventions contacts.  The results for this group were nearly identical to the all contacts 
group, with 88.5% of those in monitoring having poor adherence (RR 1.30, 95% CI [1.23, 1.38], 
p<0.001) and interventions being 2.78 times more likely to have good adherence than those in 
monitoring (95% CI [2.39, 3.25], p<0.001). 
 Contacts of secondary cases adherence.   
The results for this group were also non-significant adherence (p=0.218). 
Discussion 
 The purpose of this study was to understand the factors that contribute to poor uptake and 
adherence of LTBI treatment in Ventanilla, Peru.  This involved an analysis of data abstracted 
from treatment cards of TB patients, and analysis data from a cluster randomized controlled trial 
of a complex socioeconomic intervention with respect to uptake and adherence on LTBI 
treatment in the same community.  
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Descriptive Statistics and Analysis of Risk Factors 
 The descriptive statistics showed that 34.2% of monitoring contacts initiated treatment 
for LTBI, but that only 11.7% had good adherence, reflecting a significant need for 
understanding the factors contributing to low uptake and adherence.  This also closely reflects 
previous findings in Peru of 19% good adherence in a different urban setting (Salazar-López et 
al., 2010) and previously published abstracts of preliminary results from Ventanilla; 12% and 
22% adherent in two different studies (Iberico et al., 2011a; Iberico et al., 2011b).  These results 
reflect similar findings of very poor adherence in Malawi (uptake 22% with active case finding) 
(Zachariah et al., 2003) and Israel (28% uptake, 16% completion) (Bibi et al., 2002), indicating 
that this is not an isolated problem.  Studies in the developed economies of the US and Canada 
show significantly higher rates, but do not go above 50%. 
 In the analysis of risk factors it was clear that barriers to completion of LTBI treatment, 
just like risk factors for increased TB disease, are related to social factors.  A simple cross 
tabulation demonstrated a slight, but significant, relationship of crowding and low per capita 
income on LTBI treatment adherence rates.  There are several reasons why poverty might 
contribute to decreased uptake of, and adherence to, LTBI treatment.  A previous study in the 
same population showed that there were many hidden costs to TB therapy such as the cost of 
taking time off work and costs associated with transportation (Gavino et al., 2010).  Although 
these costs were specific to TB treatment, socio-economic incentives and enablers may be 
required for the poorest members of communities to access even free TB control interventions 
such as LTBI treatment.  One can easily appreciate the complexity of the contact screening 
process in Peru by viewing the simplified flowchart in Appendix A.  Examples of possible 
incentives include conditional items such as food baskets that are simply given to TB affected 
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persons when they show up for DOTS, and cash transfers in exchange for the completion of 
various LTBI treatment goals.  Conditional cash transfers have been demonstrated by the Juntos 
program in exchange for meeting educational and other preventive health goals (Cotlear, 2006; 
Perova & Vakis, 2009). 
 Considering how close of an association TB disease and poverty have, it was somewhat 
surprising that the socio-economic variables used in this study showed a small magnitude of 
association to LTBI treatment uptake and adherence.  This may be related to the fact that the vast 
majority of residents in Ventanilla have very low monetary income, resulting in a skewed 
distribution, and a small magnitude of difference between families above and below the median 
income level.  It is notable, however, that this finding is not in contradiction with some current 
studies.  Boccia et al. (2013) reports that her own study in Zambia, as well as multiple other 
prevalence surveys, had not found associations between single socio-economic indicators and 
prevalent TB.  A more sophisticated treatment of poverty analysis might yield different results in 
future studies. 
 This study, because of the way the data were obtained, provided little demographic 
information about the close contacts.  The author, however, was able to analyze differences in 
uptake and adherence between the two aggregate age groups (0-14 years old and 15-19 years 
old), which yielded interesting results.  Contacts in the older age group were much less likely to 
start treatment (79.8%, RR 1.29) when compared to the younger age group (61.8%).  The same 
pattern held for adherence, but the magnitude of risk was lower (95%, RR 1.10).  This reflects 
results from a survey of LTBI treatment in the USA and Canada showing adolescents older than 
fifteen to be less likely to complete treatment (Horsburgh et al., 2010), and indicates that this 
group of adolescents should be specifically targeted. 
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 The factor contributing the largest magnitude of risk in this study was that of the index 
case failing to complete treatment (RR 1.34 uptake, RR 1.13 adherence).  LTBI treatment is 
closely tied to DOTS and TB treatment of the index case.  Once every week when the index case 
goes to clinic for DOTS, the nurse will dispense the LTBI treatment doses for all contacts 
younger than 20 years old who have gone through the contact evaluation process and been 
determined not to have active TB disease.  If the index case abandons DOTS then there is no 
mechanism set up to continue to dispense LTBI treatment to contacts.  In some cases it has been 
reported that mothers will take the extra initiative to visit the health center to collect the LTBI 
treatment for their children, but this is not common.   
 Concerning index case abandonment, it was surprising that adherence did not have a 
higher relative risk compared to uptake.  One would assume that index case abandonment of 
DOTS would have little to do with uptake and more to do with adherence.  This is because LTBI 
treatment is tied to DOTS, and if an index case does not show up for directly observed therapy 
then there is no one to receive the LTBI treatment dose for the contacts.  Since abandonment 
typically occurs more frequently after a few months of DOTS, contacts should already have 
initiated treatment.  It is possible that those individuals more likely to abandon DOTS were also 
less likely to report accurately about close contacts, or have them evaluated appropriately.  This 
issue merits further research. 
Analysis of ISIAT Impact on Uptake and Adherence 
 In the analysis of ISIAT’s impact on uptake and adherence, it was clear that this complex 
intervention was more protective with regards to uptake and adherence than any of the other 
factors in the study.  It is significant to note that the interventions group only increased from 
11.7% LTBI treatment adherence to 31% treatment adherence.  Although a large and important 
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increase, it is still far below levels that would be considered adequate.  Significant operational 
barriers exist, such as drug stock-outs, use of untrained students versus program staff in data 
collection, and pressures to fulfill quotas.  The issue of quotas often drives nursing staff to devote 
more time to higher turnover areas, such as vaccine campaigns and general services (e.g. general 
medicine, or pediatrics), and less time to contact census verification, home visits, index case 
education, etc.  If the operational barriers that most affect LTBI treatment are identified and 
eliminated or improved, then these numbers might be expected to increase accordingly. 
 In this study it was not possible to differentiate contacts that had been listed twice from 
new contacts on the secondary case card.  In order to make sure that this was not affecting the all 
contacts results, the sub-analysis of index case contacts was performed.  In this sub-analysis the 
results were not significant.  If differences between index and secondary case contacts do exist 
more in-depth research is necessary to understand those differences.  One possibility is that there 
could be operational differences (i.e. the health center staff considers secondary case contacts 
less important since they have been previously assessed, and either doesn’t list them, or doesn't 
give them priority for LTBI treatment).  
Strengths 
 The major strength of this study was its large sample size, which allowed the calculation 
of relatively narrow confidence intervals, and increased the probability that these results are 
generalizable to other urban contexts in Peru and the world.  Further, the examination of index 
case characteristics is not common within the limited existing literature.  The analysis of index 
case specific variable is especially interesting because LTBI treatment uptake is contingent on 
index case reporting of contacts and receiving doses of LTBI to take to contacts.  LTBI treatment 
adherence is similarly linked to index case DOTS adherence. 
FACTORS AFFECTING LATENT TUBERCULOSIS TREATMENT 
 
56
Limitations 
 During the data cleaning process missing variables came to light, and many were not 
recoverable.  This did not allow for the most robust analysis of barriers and facilitators.  Data 
were missing due to mistakes made in the field as well as mistakes of omission made in the TB 
control office, refusal to answer on the part of study participants, or incorrectly placed dates that 
proved irretrievable.  The large sample size served to mitigate this effect, but non-response bias 
may still have affected the outcomes.  Another issue was that of contacts lost to follow up, which 
were classified as not having completed treatment.  For those individuals the length of treatment 
completed up to that point was utilized for analysis.  The majority of these contacts were truly 
non-completers, as verified by subsequent ISIAT household visits, but a minority may have 
moved to another health system and continued treatment there. 
 The aggregate nature of the anonymized data made it impossible to analyze age as a 
continuous variable, or to look at the sex or education level of individual contacts.  This was 
partly due to the surveys and the treatment cards not being specifically designed for analysis of 
factors contributing to uptake of, and adherence to, LTBI treatment.  Also, as the IRB granted to 
this project prohibited direct questioning of children under the age of eighteen, the only data 
available directly concerning children was their age range and number of weeks of treatment 
administered by the health center.  All other data was household data or index patient data.  At a 
future time it would be worth going back to examine the original health center data, and to 
question children about what facilitates or impedes starting and/or finishing treatment. 
 Defining and analyzing poverty and social class is notoriously complicated (Krieger, 
Williams, & Moss, 1997). This study used simple indicators such as income, crowding and 
education as proxies for poverty.  Various studies have shown that both simple indicators and 
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different complex calculations of socio-economic status have various effects on the results of 
analysis (Bollen, Glanville, & Stecklov, 2002; Houweling, Kunst, & Mackenbach, 2003).  
Income especially can be misleading due to its volatility, especially in poor populations such as 
the one in Ventanilla where a shift in tens of dollars per month would make a disproportionate 
impact.  In economics this is known as a decreased income elasticity of demand.  In other words, 
ten dollars per month would make a proportionately smaller impact on the demand for goods 
(including health services) in a wealthier population when compared to a poorer one.  In 
Ventanilla this could mean that using a simple indicator (income) that is highly volatile might 
not give a realistic image of a family’s true socioeconomic standing.  Unfortunately, the dataset 
did not, in its current state, allow for more complex analysis. This makes a compelling case for 
utilization of more complex methods, such as principal component analysis, to look at the data 
that ISIAT has collected on various indicators of economic well-being, including housing 
materials, domestic appliance ownership, and diet.  
Future Study 
 This author did not conduct multivariate analysis, and this should be done in future work 
to more clearly identify true facilitators and barriers.  Use of a poverty score, such as that based 
on debt, housing quality, or appliance ownership, may also have a role in future work.  Already 
ISIAT questionnaires are closely aligned with the Grameen Foundation’s Progress out of Poverty 
Index (PPI) for Peru, and could provide a source for a more accurate analysis of poverty. 
 There remains much additional research to be done in the area of LTBI treatment.  
Looking at child contacts in more detail, and considering variables such as: continuous age, 
gender of contacts, relationship to index case, caretaker information, etc. will be important in 
future work.  Studies examining operational barriers are also important.  Looking with more 
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detail at the process of contact evaluation, and, specifically, how far each contact makes it in the 
LTBI process and what reasons there might be for not starting, dropping out at certain points, or 
not completing the final physician evaluation after completion of LTBI treatment are key points 
to consider further.  There is also a difference between uptake and adherence reported on 
treatment cards (i.e. how much medication was dispensed) and the reality—what made it home 
and how many doses child and adolescent contacts actually took, which would provide an 
interesting area to apply urine tests and other methods to examine true adherence. 
Impact on Practice 
 This study opened up various possible considerations in terms of targeted interventions. 
Known issues within the ESN-PCT such as poor contact census practices, poor follow up on 
contacts, LTBI treatment administering policies varying from health center to health center are 
all likely contributing factors and seem to be more likely important factors than individual 
patient factors.  From the process of mapping the TB policy (see Appendix A), it was apparent 
that the Peruvian TB health policy document must be clarified.  Additionally, the factors 
identified in this study that may put a contact at highest risk of non-uptake and completion 
should be prioritized. These include socioeconomic status, age greater than fourteen, and index 
case abandonment.  Changes should be made considering the context and everyday job 
requirements of healthcare professionals in Ventanilla and other similar communities in Peru.  
Being a physician, nurse, or healthcare worker in these poor communities is difficult work due to 
long distances, low pay and high demands.  Interventions must be efficient and not complicate 
existing duties. 
 One interesting area for possible change is in the structure of the contact census and 
isoniazid dispensing register.  In India it has been recognized that LTBI treatment uptake is often 
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dependent on health care worker adherence to the TB control policy, and that the use of separate 
LTBI treatment registry cards for contacts can increase uptake of treatment significantly (Rekha 
et al., 2013).  In Peru it has been a longstanding policy to include these registration details on the 
back of the TB index case treatment card, unlike in the previously cited study, so the impact of a 
similar reform is unclear.  It very well could clarify the role of the census process with regards to 
LTBI treatment, and could highlight the importance of this process. It would, however, create a 
significant increase in storage space needed for contact LTBI treatment cards. 
 Treatment of LTBI for high exposure individuals should be a positive right.  At the very 
least, expanding current policy to other high risk groups such as adolescents and the elderly, who 
often have limited control of their environments, should be considered (Stop TB Partnership 
Childhood TB Subgroup, 2007).  In a back and forth correspondence between a medical student 
and the head of the TB control program in Peru in 2010, it is clear that the ministry of health 
considers it cost effective to treat LTBI in a broad range of high risk groups; including adults 
with diabetes, silicosis, gastrectomy, hematological malignancies, immunosuppressive treatment 
for another illness, terminal renal failure and renal transplants, prolonged corticosteroid therapy, 
and wasting illnesses (Jave & Llanos-Tejada, 2010; Maquera-Afaray, 2010).  Furthermore, 
influential researchers in the global tuberculosis control community have stated that DOTS for 
TB disease and LTBI treatment are synergistic, and, if used together, could lead to elimination of 
TB by 2050 (Dye & Williams, 2008).  This certainly merits a reexamination of current global 
policy with regards to treatment for LTBI in high exposure groups. 
Conclusion 
 This study has shown that in Peru, risk factors such as age, crowding, place of origin, 
index case abandonment, and establishment in Lima are significant risk factors for uptake and 
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adherence of LTBI treatment (summarized in Table 9).  Additionally, this study has shown that a 
relatively inexpensive panel of socio-economic interventions designed for TB-affected 
households living in impoverished periurban shantytowns was associated with a marked increase 
in uptake of, and adherence to, LTBI treatment, resulting in strengthened TB control (Table 8). 
Table 9  
Summary of Risk Factors (p<0.05) 
 
 No Uptake RR 
Poor 
Adherence 
RR 
Age 15-19 79.0% 1.29 95% 1.10 
Crowded * 70.9% 1.10 92.5% 1.06 
IC Born in:     
Other Lima Metro ** 64.8% 1.08 92.0% 1.10 
Central 55.8% 0.86 80.9% 0.90 
IC abandoned DOTS 81.3% 1.34 96.6% 1.13 
IC lived in Lima <2 years 67.6% 1.15 90.6% 1.07 
Note: DOTS = directly observed therapy short course; IC = index case; RR = relative risk 
* Crowded defined as nine or more people in one household 
** Refers to Lima Metropolitan Area, which includes both Callao and Lima 
 
  
FACTORS AFFECTING LATENT TUBERCULOSIS TREATMENT 
 
61
References 
American Thoracic Society, Centers for Disease Control and Prevention, Infectious Diseases 
Society of America (ATS/CDC/IDSA). (2000). Targeted tuberculin testing and treatment 
of latent tuberculosis infection. American Journal of Respiratory and Critical Care 
Medicine, 161(4 Pt 2), S221-247. doi:10.1164/ajrccm.161.supplement_3.ats600 
Aminzadeh, Z., & Asl, R. T. (2011). A six months follow-up on children less than 6 years old in 
contact with smear positive tuberculosis patients, Varamin city, Tehran, Iran. 
International Journal of Preventive Medicine, 2(2), 79-81. 
Amrith, S. (2002, December 11). Plague of poverty?: The World Health Organization, 
Tuberculosis and International Development, c. 1945-1980. 
http://www.histecon.magd.cam.ac.uk/docs/amrith_WHO.pdf. (E. Rothschild, Ed.). 
Cambridge; Christ’s College. 
Balcells, M. E., Thomas, S. L., Godfrey-Faussett, P., & Grant, A. D. (2006). Isoniazid preventive 
therapy and risk for resistant tuberculosis. Emerging Infectious Diseases, 12(5), 744-751. 
Barry, C. E., Boshoff, H. I., Dartois, V., Dick, T., Ehrt, S., Flynn, J. … Young, D. (2009). The 
spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nature 
Reviews Microbiology, 7(12), 845-855. doi:10.1038/nrmicro2236 
Bass, J. B., Farer, L. S., Hopewell, P. C., O'Brien, R., Jacobs, R. F., Ruben, F. … Thornton, G. 
(1994). Treatment of tuberculosis and tuberculosis infection in adults and children. 
American Journal of Respiratory and Critical Care Medicine, 149(5), 1359-1374. 
doi:10.1164/ajrccm.149.5.8173779 
Bayer, R., & Wilkinson, D. (1995). Directly observed therapy for tuberculosis: History of an 
idea. The Lancet, 345(8964), 1545-1548. 
FACTORS AFFECTING LATENT TUBERCULOSIS TREATMENT 
 
62
Bibi, H., Weiler-Ravell, D., Shoseyov, D., Feigin, I., Arbelli, Y., & Chemtob, D. (2002). 
Compliance to treatment of latent tuberculosis infection in a region of Israel. The Israel 
Medical Association Journal, 4(1), 13-16. 
Blower, S. M., McLean, A. R., Porco, T. C., Small, P. M., Hopewell, P. C., Sanchez, M. A., & 
Moss, A. R. (1995). The intrinsic transmission dynamics of tuberculosis epidemics. 
Nature Medicine, 1(8), 815-821. 
Boccia, D., Hargreaves, J. R., Ayles, H., Fielding, K., Simwinga, M., & Godfrey-Faussett, P. 
(2009). Tuberculosis infection in Zambia: The association with relative wealth. The 
American Journal of Tropical Medicine and Hygiene, 80(6), 1004-1011. 
Boccia, D., Hargreaves, J. R., Howe, L. D., De Stavola, B. L., Fielding, K., Ayles, H., & 
Godfrey-Faussett, P. (2013). The measurement of household socio-economic position in 
tuberculosis prevalence surveys: A sensitivity analysis. The International Journal of 
Tuberculosis and Lung Disease, 17(1), 39-45. doi:10.5588/ijtld.11.0387 
Bollen, K. A., Glanville, J. L., & Stecklov, G. (2002). Economic status proxies in studies of 
fertility in developing countries: Does the measure matter? Population Studies, 56(1), 81-
96. doi:10.1080/00324720213796 
Brailey, M. (1940). Mortality in the Children of Tuberculous Households. American Journal of 
Public Health and the Nation's Health, 30(7), 816-823. 
Bright-Thomas, R., Nandwani, S., Smith, J., Morris, J. A., & Ormerod, L. P. (2010). 
Effectiveness of 3 months of rifampicin and isoniazid chemoprophylaxis for the 
treatment of latent tuberculosis infection in children. Archives of Disease in Childhood, 
95(8), 600-602. doi:10.1136/adc.2010.182600 
FACTORS AFFECTING LATENT TUBERCULOSIS TREATMENT 
 
63
Bush, K. (2010). The coming of age of antibiotics: Discovery and therapeutic value. Annals of 
the New York Academy of Sciences, 1213, 1-4. doi:10.1111/j.1749-6632.2010.05872.x 
Centers for Disease Control and Prevention (CDC). (2010). Extensively drug-resistant 
tuberculosis: “there must be some kind of way out of here.” Clinical Infectious Diseases, 
50(Suppl 3), S195-200. doi:10.1086/651491 
Centers for Disease Control and Prevention (CDC). (2011). Recommendations for use of an 
isoniazid-rifapentine regimen with direct observation to treat latent mycobacterium 
tuberculosis infection. Morbidity and Mortality Weekly Report, 60(48), 1650-1653. 
Centers for Disease Control and Prevention, American Thoracic Society, Infectious Diseases 
Society of America (CDC/ATS/IDSA). (2000). Targeted Tuberculin Testing and 
Treatment of Latent Tuberculosis infection. Morbidity and Mortality Weekly Report, 
49(RR-6), 1-71. Retrieved from http://www.cdc.gov/mmwr/pdf/rr/rr4906.pdf 
Chen, S.-C., Chen, K.-L., Chen, K.-H., Chien, S.-T., & Chen, K.-T. (2013). Updated diagnosis 
and treatment of childhood tuberculosis. World Journal of Pediatrics, 9(1), 9-16. 
doi:10.1007/s12519-013-0404-6 
Cohn, D. L., & El-Sadr, W. M. (2006). Treatment of latent tuberculosis infection. In M. C. 
Raviglione (Ed.), Reichman and Hershfield's Tuberculosis: A comprehensive, 
international approach (pp. 265-306). New York: Informa Healthcare. 
Comstock, G. W. (1962). Isoniazid prophylaxis in an undeveloped area. American Review of 
Respiratory Disease, 86, 810-822. 
Comstock, G. W. (1999). How much isoniazid is needed for prevention of tuberculosis among 
immunocompetent adults? The International Journal of Tuberculosis and Lung Disease, 
3(10), 847-850. 
FACTORS AFFECTING LATENT TUBERCULOSIS TREATMENT 
 
64
Comstock, G. W., Baum, C., & Snider, D. E. (1979). Isoniazid prophylaxis among Alaskan 
Eskimos: A final report of the bethel isoniazid studies. The American Review of 
Respiratory Disease, 119(5), 827-830. 
Cotlear, D. (2006). A new social contract for Peru: An agenda for improving education, health 
care, and the social safety net (pp. 1-330). (A World Bank Country Study) Washington, 
D.C.: World Bank. doi:10.1596/978-0-8213-6567-0 
Cruz, A. T., & Starke, J. R. (2013). Twice-weekly therapy for children with tuberculosis 
infection or exposure. The International Journal of Tuberculosis and Lung Disease, 
17(2), 169-174. doi:10.5588/ijtld.12.0641 
Daniel, T. M. (2005). Selman Abraham Waksman and the discovery of streptomycin. The 
International Journal of Tuberculosis and Lung Disease, 9(2), 120-122. 
Dheda, K., & Migliori, G. B. (2011). The global rise of extensively drug-resistant tuberculosis: Is 
the time to bring back sanatoria now overdue? The Lancet, 379(9817), 773-775. 
doi:10.1016/S0140-6736(11)61062-3 
Dheda, K., Smit, R. V. Z., Badri, M., & Pai, M. (2009). T-cell interferon-γ release assays for the 
rapid immunodiagnosis of tuberculosis: clinical utility in high-burden vs. low-burden 
settings. Current Opinion in Pulmonary Medicine, 15(3), 188-200. 
doi:10.1097/MCP.0b013e32832a0adc 
Dubos, R. J., & Dubos, J. (1987). The white plague: Tuberculosis man and society. New 
Brunswick: Rutgers University Press. 
Dye, C. C. (2011). Practical preventive therapy for tuberculosis? The New England Journal of 
Medicine, 365(23), 2230-2231. doi:10.1056/NEJMe1111859 
FACTORS AFFECTING LATENT TUBERCULOSIS TREATMENT 
 
65
Dye, C. C., & Floyd, K. (2006). Tuberculosis. In D. T. Jamison, J. G. Breman, A. R. Measham, 
G. Alleyne, M. Claeson, D. B. Evans, et al. (Eds.), Disease control priorities in 
developing countries (pp. 289-309). New York: Oxford University Press. 
Dye, C. C., & Williams, B. G. (2008). Eliminating human tuberculosis in the twenty-first 
century. Journal of the Royal Society Interface, 5(23), 653-662. 
doi:10.1098/rsif.2007.1138 
Enarson, D. A., Rieder, H. L., Arnadottir, T., & Trébucq, A. (2000). Management of 
tuberculosis: A guide for low income countries. (International Union Against 
Tuberculosis and Lung Disease, Ed.) (5 ed.). Paris: The International Union Against 
Tuberculosis and Lung Disease. 
Estrategia Sanitaria Nacional de Prevencion y Control de la Tuberculosis, Ministerio de Salud 
Peru, Direccion General de Salud de las Personas. (2006). Norma Tecnica de Salud Para 
el Control de la Tuberculosis. Lima: Ministerio de Salud. Retrieved from 
ftp://ftp2.minsa.gob.pe/descargas/dgsp/ESN-
tuberculosis/normaspublicaciones/NTSTBC.pdf 
Farmer, P. E. (2000). The Consumption of the poor: Tuberculosis in the 21st century. 
Ethnography, 1(2), 183-216. doi:10.1177/14661380022230732 
Farmer, P., & Kim, J. Y. (1998). Community based approaches to the control of multidrug 
resistant tuberculosis: introducing "DOTS-plus". British Medical Journal, 317(7159), 
671-674. 
Flynn, J. L., & Chan, J. (2001). Tuberculosis: Latency and reactivation. Infection and Immunity, 
69(7), 4195-4201. doi:10.1128/IAI.69.7.4195-4201.2001 
FACTORS AFFECTING LATENT TUBERCULOSIS TREATMENT 
 
66
Fong, I. W. (2013). Multidrug-resistant tuberculosis: A global challenge. In I. W. Fong (Ed.), 
Challenges in infectious diseases (pp. 89-119). New York: Springer. 
Fox, G. J., & Menzies, D. (2013). Epidemiology of tuberculosis immunology. In N. Curtis, A. 
Finn, & A. J. Pollard (Eds.), Advances in experimental medicine and biology (Vol. 783, 
pp. 1-32). New York: Springer. doi:10.1007/978-1-4614-6111-1_1 
Franke, M. F., Appleton, S. C., Mitnick, C. D., Furin, J. J., Bayona, J., Chalco, K., . . . Becerra, 
M. (2013). Aggressive regimens for multidrug-resistant tuberculosis reduce recurrence. 
Clinical Infectious Diseases, 56(6), 770-776. doi:10.1093/cid/cis1008 
Gandy, M. (2003). Life Without Germs: Contested Episodes in the History of Tuberculosis. In 
The return of the white plague (pp. 15-38). London: Verso Books. 
Gavino, A., Montoya, R., Alva, J., Franco, J., Valiente, B., Rivero, A. M., . . . Evans, C. A. 
(2010). The true costs for patients to receive free TB and MDR-TB care. 41st Union 
World Conference on Lung Health, November 2011. Berlin. 
Geng, E., Kreiswirth, B., Driver, C., Li, J., Burzynski, J., DellaLatta, P., . . . Schluger, N. W. 
(2002). Changes in the transmission of tuberculosis in New York City from 1990 to 1999. 
The New England Journal of Medicine, 346(19), 1453-1458. 
doi:10.1056/NEJMoa012972 
Glaziou, P., Falzon, D., Floyd, K., & Raviglione, M. (2013). Global Epidemiology of 
Tuberculosis. Seminars in Respiratory and Critical Care Medicine, 34(1), 3-16. 
doi:10.1055/s-0032-1333467 
Goswami, N. D., Gadkowski, L. B., Piedrahita, C., Bissette, D., Ahearn, M. A., Blain, M. L. M., 
. . . Stout, J. E. (2012). Predictors of latent tuberculosis treatment initiation and 
FACTORS AFFECTING LATENT TUBERCULOSIS TREATMENT 
 
67
completion at a U.S. public health clinic: A prospective cohort study. BMC Public 
Health, 12, 468. doi:10.1186/1471-2458-12-468 
Gupta, A., Kaul, A., Tsolaki, A. G., Kishore, U., & Bhakta, S. (2012). Mycobacterium 
tuberculosis: Immune evasion, latency and reactivation. Immunobiology, 217(3), 363-
374. doi:10.1016/j.imbio.2011.07.008 
Harries, A. D., & Dye, C. C. (2006). Tuberculosis. Annals of Tropical Medicine and 
Parasitology, 100(5-6), 415–431. doi:10.1179/136485906X91477 
Hershkovitz, I., Donoghue, H. D., Minnikin, D. E., Besra, G. S., Lee, O. Y.-C., Gernaey, A. M., . 
. . Lema, E. (2008). Detection and molecular characterization of 9,000-year-old 
Mycobacterium tuberculosis from a Neolithic settlement in the Eastern Mediterranean. 
PloS one, 3(10). e3426. doi:10.1371/journal.pone.0003426 
Hirsch-Moverman, Y., Daftary, A., Franks, J., & Colson, P. W. (2008). Adherence to treatment 
for latent tuberculosis infection: Systematic review of studies in the US and Canada. The 
International Journal of Tuberculosis and Lung Disease, 12(11), 1235-1254. 
Horsburgh, C. R. (2004). Priorities for the treatment of latent tuberculosis infection in the United 
States. The New England Journal of Medicine, 350(20), 2060-2067. 
doi:10.1056/NEJMsa031667 
Horsburgh, C. R., Goldberg, S., Bethel, J., Chen, S., Colson, P. W., Hirsch-Moverman, Y., . . . 
Weinfurter, P. (2010). Latent TB infection treatment acceptance and completion in the 
United States and Canada. Chest, 137(2), 401-409. doi:10.1378/chest.09-0394 
Houweling, T. A., Kunst, A. E., & Mackenbach, J. P. (2003). Measuring health inequality among 
children in developing countries: Does the choice of the indicator of economic status 
matter? International Journal for Equity in Health, 2(1), 8. doi:10.1186/1475-9276-2-8 
FACTORS AFFECTING LATENT TUBERCULOSIS TREATMENT 
 
68
Hovell, M. F., Blumberg, E. J., Gil-Trejo, L., Vera, A., Kelley, N., Sipan, C., . . . Moser, K. 
(2003a). Predictors of adherence to treatment for latent tuberculosis infection in high-risk 
Latino adolescents: a behavioral epidemiological analysis. Social Science & Medicine 
(1982), 56(8), 1789-1796. 
Hovell, M. F., Sipan, C. L., Blumberg, E. J., Hofstetter, C. R., Slymen, D., Friedman, L., et al. 
(2003b). Increasing Latino adolescents' adherence to treatment for latent tuberculosis 
infection: A controlled trial. American Journal of Public Health, 93(11), 1871-1877. 
Hsu, K. H. (1984). Thirty years after isoniazid. Its impact on tuberculosis in children and 
adolescents. Journal of the American Medical Association, 251(10), 1283-1285. 
Iberico, M. M., Zevallos, K., Boccia, D., Tovar, M. A., Gavino, A., Valiente, B., . . . Rocha, C. 
(2011a). Uptake and equity of tuberculosis preventive therapy was increased by a 
socioeconomic intervention. Poster presented at the 2011 Global Health Conference, 
Montreal, Quebec. 
Iberico, M. M., Zevallos, K., Valiente, B., Montoya, R., Curatola, A., Tovar, M. A., . . . Evans, 
C. A. (2011b). Poverty impairs isoniazid preventative therapy for children in Peru. 
Poster presented at the 42nd Union World Conference on Lung Health. Lille, France. 
Instituto Nacional de Estadistica e Informatica [INEI]. (n.d.). Sistema de Consulta de Resultados 
Censales. Retrieved from 
http://desa.inei.gob.pe/censos2007/tabulados/?id=ResultadosCensales 
Instituto Nacional de Estadistica e Informática [INEI], United Nations [UN]. (2009). PERÚ: 
Estimaciones y Proyecciones de Población por Sexo, según Departamento, Provincia y 
Distrito, 2000-2015: Boletín especial N 18 (pp. 1-394). Lima: Instituto Nacional de 
FACTORS AFFECTING LATENT TUBERCULOSIS TREATMENT 
 
69
Estadística e Informática. Retrieved from 
http://www.inei.gob.pe/biblioineipub/bancopub/Est/Lib0842/ 
Jave, O., & Llanos-Tejada, F. (2010). Réplica de la estrategia sanitaria nacional de prevención y 
control de la tuberculosis. Revista Peruana de Medicina Experimental y Salud Pública, 
27(2), 301-306. 
Joshi, R., Reingold, A. L., Menzies, D., & Pai, M. (2006). Tuberculosis among health-care 
workers in low- and middle-income countries: A systematic review. PLoS Medicine, 
3(12). e494. doi:10.1371/journal.pmed.0030494 
Kappelman, J., Alçiçek, M. C., Kazanci, N., Schultz, M., Ozkul, M., & Sen, S. (2008). First 
Homo erectus from Turkey and implications for migrations into temperate Eurasia. 
American Journal of Physical Anthropology, 135(1), 110-116. doi:10.1002/ajpa.20739 
Keshavjee, S., & Farmer, P. E. (2013). History of tuberculosis and drug resistance. The New 
England Journal of Medicine, 368(1), 89-90. doi:10.1056/NEJMc1212308 
Krieger, N., Williams, D. R., & Moss, N. E. (1997). Measuring social class in US public health 
research: concepts, methodologies, and guidelines. Annual Review of Public Health, 18, 
341-378. doi:10.1146/annurev.publhealth.18.1.341 
Lester, R., Hamilton, R., Charalambous, S., Dwadwa, T., Chandler, C. I. R., Churchyard, G. J., 
& Grant, A. D. (2010). Barriers to implementation of isoniazid preventive therapy in HIV 
clinics: a qualitative study. AIDS, 24(Suppl 5), S45-S48. 
doi:10.1097/01.aids.0000391021.18284.12 
Leung, C. C., Rieder, H. L., Lange, C., & Yew, W. W. (2011). Treatment of latent infection with 
Mycobacterium tuberculosis: Update 2010. European Respiratory Journal, 37(3), 690-
711. doi:10.1183/09031936.00079310 
FACTORS AFFECTING LATENT TUBERCULOSIS TREATMENT 
 
70
Li, J., Munsiff, S. S., Tarantino, T., & Dorsinville, M. (2010). Adherence to treatment of latent 
tuberculosis infection in a clinical population in New York City. International Journal of 
Infectious Diseases, 14(4), e292-e297. doi:10.1016/j.ijid.2009.05.007 
LoBue, P. A., & Moser, K. S. (2003). Use of isoniazid for latent tuberculosis infection in a 
public health clinic. American Journal of Respiratory and Critical Care Medicine, 
168(4), 443-447. doi:10.1164/rccm.200303-390OC 
LoBue, P., & Menzies, D. (2010). Treatment of latent tuberculosis infection: An update. 
Respirology (Carlton, Vic.), 15(4), 603-622. doi:10.1111/j.1440-1843.2010.01751.x 
Lonnroth, K., Castro, K. G., Chakaya, J. M., Chauhan, L. S., Floyd, K., Glaziou, P., & 
Raviglione, M. C. (2010). Tuberculosis control and elimination 2010-50: Cure, care, and 
social development. The Lancet, 375(9728), 1814-1829. doi:10.1016/S0140-
6736(10)60483-7 
Machado, A., Jr, Finkmoore, B., Emodi, K., Takenami, I., Barbosa, T., Tavares, M., . . . Riley, L. 
W. (2009). Risk factors for failure to complete a course of latent tuberculosis infection 
treatment in Salvador, Brazil. The International Journal of Tuberculosis and Lung 
Disease, 13(6), 719-725. 
Mack, U., Migliori, G. B., Sester, M., & Rieder, H. L. (2009). LTBI: Latent tuberculosis 
infection or lasting immune responses to M. tuberculosis? A TBNET consensus 
statement. The European Respiratory Journal, 33(5), 956-973. 
Maquera-Afaray, J. (2010). Tuberculosis latente: cobertura quimioprofiláctica de contactos 
intradomiciliarios en el Perú. Revista Peruana de Medicina Experimental y Salud 
Pública, 27(2), 302-303. 
FACTORS AFFECTING LATENT TUBERCULOSIS TREATMENT 
 
71
Marais, B. J. (2008). Tuberculosis in children. Pediatric Pulmonology, 43(4), 322-329. 
doi:10.1002/ppul.20787 
Marais, B. J., Gie, R. P., Schaaf, H. S., Hesseling, A. C., Obihara, C. C., Starke, J. J., . . . Beyers, 
N. (2004). The natural history of childhood intra-thoracic tuberculosis: a critical review 
of literature from the pre-chemotherapy era. The International Journal of Tuberculosis 
and Lung Disease, 8(4), 392-402. 
Marais, B. J., van Zyl, S., Schaaf, H. S., van Aardt, M., Gie, R. P., & Beyers, N. (2006). 
Adherence to isoniazid preventive chemotherapy: a prospective community based study. 
Archives of Disease in Childhood, 91(9), 762-765. doi:10.1136/adc.2006.097220 
Martinson, N. A., Barnes, G. L., Moulton, L. H., Msandiwa, R., Hausler, H., Ram, M., . . . 
Chaisson, R. E. (2011). New regimens to prevent tuberculosis in adults with HIV 
infection. The New England Journal of Medicine, 365(1), 11-20. 
doi:10.1056/NEJMoa1005136 
McKeown, T. (2005). Medical issues in historical demography. International Journal of 
Epidemiology, 34(3), 515-520. doi:10.1093/ije/dyh195 
Mendoza, A., Castillo, E., Gamarra, N., Huamán, T., Perea, M., Monroi, Y., . . . Moore, D. A. J. 
(2011). Reliability of the MODS assay decentralisation process in three health regions in 
Peru. The International Journal of Tuberculosis and Lung Disease, 15(2), 217-222-i. 
Menzies, D., & Doherty, T. M. (2006). Diagnosis of Latent Tuberculosis Infection. In M. C. 
Raviglione (Ed.), Reichman and Hershfield's Tuberculosis: A Comprehensive, 
International Approach (pp. 215–264). New York: Informa Healthcare. 
Montenegro, S. H., Gilman, R. H., Sheen, P., Cama, R., Caviedes, L., Hopper, T., . . . 
Oberhelman, R. A. (2003). Improved detection of Mycobacterium tuberculosis in 
FACTORS AFFECTING LATENT TUBERCULOSIS TREATMENT 
 
72
Peruvian children by use of a heminested IS6110 polymerase chain reaction assay. 
Clinical Infectious Diseases, 36(1), 16-23. doi:10.1086/344900 
Moore, D. A. J., Evans, C. A. W., Gilman, R. H., Caviedes, L., Coronel, J., Vivar, A., . . . 
Friedland, J. S. (2006). Microscopic-observation drug-susceptibility assay for the 
diagnosis of TB. The New England Journal of Medicine, 355(15), 1539-1550. 
doi:10.1056/NEJMoa055524 
Morrison, J., Pai, M., & Hopewell, P. C. (2008). Tuberculosis and latent tuberculosis infection in 
close contacts of people with pulmonary tuberculosis in low-income and middle-income 
countries: A systematic review and meta-analysis. The Lancet Infectious Diseases, 8(6), 
359-368. doi:10.1016/S1473-3099(08)70071-9 
Murray, M., Oxlade, O., & Lin, H.-H. (2011). Modeling social, environmental and biological 
determinants of tuberculosis. The International Journal of Tuberculosis and Lung 
Disease, 15(6), 64-70. doi:10.5588/ijtld.10.0535 
Nelson, L. J., & Wells, C. D. (2004). Global epidemiology of childhood tuberculosis. The 
International Journal of Tuberculosis and Lung Disease, 8(5), 636-647. 
Ngamvithayapong, J., Uthaivoravit, W., Yanai, H., Akarasewi, P., & Sawanpanyalert, P. (1997). 
Adherence to tuberculosis preventive therapy among HIV-infected persons in Chiang 
Rai, Thailand. AIDS, 11(1), 107-112. 
Nyirenda, M., Sinfield, R., Haves, S., Molyneux, E. M., & Graham, S. M. (2006). Poor 
attendance at a child TB contact clinic in Malawi. The International Journal of 
Tuberculosis and Lung Disease, 10(5), 585-587. 
FACTORS AFFECTING LATENT TUBERCULOSIS TREATMENT 
 
73
Onifade, D. A., Bayer, A. M., Montoya, R., Haro, M., Alva, J., Franco, J., . . . Evans, C. A. 
(2010). Gender-related factors influencing tuberculosis control in shantytowns: a 
qualitative study. BMC Public Health, 10. 381. doi:10.1186/1471-2458-10-381 
Parsyan, A. E., Saukkonen, J., Barry, M. A., Sharnprapai, S., & Horsburgh, C. R. (2007). 
Predictors of failure to complete treatment for latent tuberculosis infection. The Journal 
of Infection, 54(3), 262-266. doi:10.1016/j.jinf.2006.04.010 
Perova, E., & Vakis, R. (2009). Welfare impacts of the “Juntos” Program in Peru: Evidence from 
a non-experimental evaluation. The World Bank, 1-59. 
Raviglione, M. C., & Pio, A. (2002). Evolution of WHO policies for tuberculosis control, 1948-
2001. The Lancet, 359(9308), 775-780. 
Reichler, M. R., Reves, R., Bur, S., Ford, J., Thompson, V., Mangura, B., et al. (2002). 
Treatment of latent tuberculosis infection in contacts of new tuberculosis cases in the 
United States. Southern Medical Journal, 95(4), 414-420. 
Rekha, B., Jagarajamma, K., Chandrasekaran, V., Wares, F., Sivanandham, R., & Swaminathan, 
S. (2013). Improving screening and chemoprophylaxis among child contacts in India's 
RNTCP: A pilot study. The International Journal of Tuberculosis and Lung Disease, 
17(2), 163-168. doi:10.5588/ijtld.12.0415 
Riley, R. L. (1974). Airborne infection. The American Journal of Medicine, 57(3), 466-475. 
Rocha, C., Montoya, R., Zevallos, K., Curatola, A., Ynga, W., Franco, J., . . . Evans, C. A. 
(2011). The Innovative Socio-economic Interventions Against Tuberculosis (ISIAT) 
project: An operational assessment. The International Journal of Tuberculosis and Lung 
Disease, 15(Suppl 2), 50-57. doi:10.5588/ijtld.10.0447 
FACTORS AFFECTING LATENT TUBERCULOSIS TREATMENT 
 
74
Rothschild, B. M., Martin, L. D., Lev, G., Bercovier, H., Bar-Gal, G. K., Greenblatt, C., . . . 
Brittain, D. (2001). Mycobacterium tuberculosis complex DNA from an extinct bison 
dated 17,000 years before the present. Clinical Infectious Diseases, 33(3), 305-311. 
doi:10.1086/321886 
Rowe, K. A., Makhubele, B., Hargreaves, J. R., Porter, J. D., Hausler, H. P., & Pronyk, P. M. 
(2005). Adherence to TB preventive therapy for HIV-positive patients in rural South 
Africa: Implications for antiretroviral delivery in resource-poor settings? The 
International Journal of Tuberculosis and Lung Disease, 9(3), 263-269. 
Rutherford, M. E., Ruslami, R., Maharani, W., Yulita, I., Lovell, S., van Crevel, R., . . . Hill, P. 
C. (2012). Adherence to isoniazid preventive therapy in Indonesian children: A 
quantitative and qualitative investigation. BMC Research Notes, 5. 7. doi:10.1186/1756-
0500-5-7 
Salazar-López, M. E., Arévalo-Abanto, J., & Ticona-Chávez, E. (2010). Cumplimiento de la 
quimioprofilaxis con isoniacida y factores asociados en pacientes infectados con el VIH 
en el Hospital Nacional Dos de Mayo. Revista Peruana de Epidemiología, 16(3), 1-7. 
Schaible, U. E., & Kaufmann, S. H. E. (2007). Malnutrition and infection: complex mechanisms 
and global impacts. PLoS Medicine, 4(5), 806-812. doi:10.1371/journal.pmed.0040115 
Sebastian, M. S., & Bothamley, G. H. (2000). Tuberculosis preventive therapy: Perspective from 
a multi-ethnic community. Respiratory Medicine, 94(7), 648-653. 
Selwyn, P. A., Hartel, D., Lewis, V. A., Schoenbaum, E. E., Vermund, S. H., Klein, R. S., . . . 
Friedland, G. H. (1989). A prospective study of the risk of tuberculosis among 
intravenous drug users with human immunodeficiency virus infection. The New England 
Journal of Medicine, 320(9), 545-550. doi:10.1056/NEJM198903023200901 
FACTORS AFFECTING LATENT TUBERCULOSIS TREATMENT 
 
75
Sharma, S. K., Mohanan, S., & Sharma, A. (2012). Relevance of latent TB infection in areas of 
high TB prevalence. Chest, 142(3), 761-773. doi:10.1378/chest.12-0142 
Shin, S. S., Yagui, M., Ascencios, L., Yale, G., Suarez, C., Quispe, N., . . . Cegielski, P (2008). 
Scale-up of multidrug-resistant tuberculosis laboratory services, Peru. Emerging 
Infectious Diseases, 14(5), 701-708. 
Singh, V., & Patra, S. (2011). A relook at preventive therapy for tuberculosis in children. Indian 
journal of pediatrics, 78(2), 205-210. doi:10.1007/s12098-010-0257-0 
Smith-Nonini, S. (2005). When “the program is good, but the disease is better”: Lessons from 
Peru on drug-resistant tuberculosis. Medical Anthropology, 24(3), 265-296. 
doi:10.1080/01459740500189548 
Sterling, T. R., Villarino, M. E., Borisov, A. S., Shang, N., Gordin, F., Bliven-Sizemore, E., . . . 
Chaisson, R. E. (2011). Three months of rifapentine and isoniazid for latent tuberculosis 
infection. The New England Journal of Medicine, 365(23), 2155-2166. 
doi:10.1056/NEJMoa1104875 
Stop TB Partnership. (2006). The global plan to stop tb 2006-2015: Actions for life: Towards a 
world free of tuberculosis. WHO press. Retrieved from 
http://whqlibdoc.who.int/publications/2006/9241593997_eng.pdf 
Stop TB Partnership Childhood TB Subgroup. (2007). Guidance for national tuberculosis 
programmes on the management of tuberculosis in children. Chapter 4: Childhood 
contact screening and management. International Journal of Tuberculosis and Lung 
Disease, 11(1), 12-15. Retrieved from 
http://www.who.int/maternal_child_adolescent/documents/htm_tb_2006_371/en/ 
FACTORS AFFECTING LATENT TUBERCULOSIS TREATMENT 
 
76
Styblo, K. (1980). Recent advances in epidemiological research in tuberculosis. Advances in 
Tuberculosis Research, 20, 1-63. 
Swaminathan, S., & Rekha, B. (2010). Pediatric tuberculosis: Global overview and challenges. 
Clinical Infectious Diseases, 50(s3), S184-S194. doi:10.1086/651490 
Tiemersma, E. W., van der Werf, M. J., Borgdorff, M. W., Williams, B. G., & Nagelkerke, N. J. 
D. (2011). Natural history of tuberculosis: Duration and fatality of untreated pulmonary 
tuberculosis in HIV negative patients: A systematic review. PloS one, 6(4), e17601. 
doi:10.1371/journal.pone.0017601 
Toit, K., Mitchell, S., Balabanova, Y., Evans, C. A. W., Kummik, T., Nikolayevskyy, V., & 
Drobniewski, F. (2012). The Colour Test for drug susceptibility testing of 
Mycobacterium tuberculosis strains. The International Journal of Tuberculosis and Lung 
Disease, 16(8), 1113-1118. doi:10.5588/ijtld.11.0609 
Tornee, S., Kaewkungwal, J., Fungladda, W., Silachamroon, U., Akarasewi, P., & Sunakorn, P. 
(2005). Factors associated with the household contact screening adherence of 
tuberculosis patients. The Southeast Asian Journal of Tropical Medicine and Public 
Health, 36(2), 331-340. 
Trajman, A., Long, R., Zylberberg, D., Dion, M. J., Al-Otaibi, B., & Menzies, D. (2010). Factors 
associated with treatment adherence in a randomised trial of latent tuberculosis infection 
treatment. The International Journal of Tuberculosis and Lung Disease, 14(5), 551-559. 
Trajman, A., Steffen, R. E., & Menzies, D. (2013). Interferon-gamma release assays versus 
tuberculin skin testing for the diagnosis of latent tuberculosis infection: An overview of 
the evidence. Pulmonary Medicine, 2013, Article ID 601737. doi:10.1155/2013/601737 
United Nations [UN]. (2008). MDG Goal 6, 1–2. 
FACTORS AFFECTING LATENT TUBERCULOSIS TREATMENT 
 
77
van Zyl, S., Marais, B. J., Hesseling, A. C., Gie, R. P., Beyers, N., & Schaaf, H. S. (2006). 
Adherence to anti-tuberculosis chemoprophylaxis and treatment in children. The 
International Journal of Tuberculosis and Lung Disease, 10(1), 13-18. 
Vernon, A. (2013). Treatment of latent tuberculosis infection. Seminars in Respiratory and 
Critical Care Medicine, 34(1), 67-86. doi:10.1055/s-0032-1333544 
Wallace, D. N. (2001). Discriminatory public policies and the New York City tuberculosis 
epidemic, 1975-1993. Microbes and Infection, 3(6), 515-524. 
Whalen, C. C., Zalwango, S., Chiunda, A., Malone, L., Eisenach, K., Joloba, M., . . . Mugerwa, 
R. (2011). Secondary attack rate of tuberculosis in urban households in Kampala, 
Uganda. PloS one, 6(2), e16137. doi:10.1371/journal.pone.0016137.s001 
World Bank. (n.d.). Peru Data. World Bank Data. Retrieved from 
http://data.worldbank.org/country/peru 
World Health Organization (WHO). (1948). Report of the expert committee on tuberculosis: 
First session, held at the Office International d'Hygiène Publique, Paris, 30 July - 2 
August 1947. Bulletin of the World Health Organization, 1(2), 205-208. 
World Health Organization (WHO) WHO/CDS/CPC/TB/99.270. (1999). What is DOTS?: A 
guide to understanding the WHO-recommended TB control strategy known as DOTS. 
Retrieved from http://whqlibdoc.who.int/hq/1999/WHO_CDS_CPC_TB_99.270.pdf 
World Health Organization (WHO). (2007). Control of XDR-TB: Update on progress since the 
Global Task Force on XDR-TB meeting in 2006. World Health Organization. Retrieved 
from 
http://www.stoptb.org/events/world_tb_day/2007/assets/documents/globaltaskforce_upda
te_feb07.pdf 
FACTORS AFFECTING LATENT TUBERCULOSIS TREATMENT 
 
78
World Health Organization (WHO). (2011). Global Tuberculosis Control: WHO Report 2011 
(pp. 1–258). Geneva: WHO Press. Retrieved from 
http://whqlibdoc.who.int/publications/2011/9789241564380_eng.pdf 
World Health Organization (WHO). (2012). Global Tuberculosis Report 2012. Geneva: WHO 
Press. Retrieved from 
http://apps.who.int/iris/bitstream/10665/75938/1/9789241564502_eng.pdf 
Zachariah, R., Spielmann, M. P., Harries, A. D., Gomani, P., Graham, S. M., Bakali, E., & 
Humblet, P. (2003). Passive versus active tuberculosis case finding and isoniazid 
preventive therapy among household contacts in a rural district of Malawi. The 
International Journal of Tuberculosis and Lung Disease, 7(11), 1033-1039. 
Zumla, A. I., Mwaba, P., Huggett, J., Kapata, N., Chanda, D., & Grange, J. M. (2009). 
Reflections on the white plague. The Lancet Infectious Diseases, 9(3), 197-202. 
doi:10.1016/S1473-3099(09)70045-3 
Zuñiga, J. A. (2012). Medication adherence in Hispanics to latent tuberculosis treatment: A 
literature review. Journal of Immigrant and Minority Health, 14(1), 23-29. 
doi:10.1007/s10903-010-9393-x 
FACTORS AFFECTING LATENT TUBERCULOSIS TREATMENT 79
APPENDIX A: TB Control Policy: Simplified Contact Assessment Flow-Chart 
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APPENDIX B: Treatment Card Example (redacted) 
 
FRONT 
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BACK 
 
Record of LTBI treatment weekly dose dispensing 
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APPENDIX C: Images for Context 
 
This is a view of Ventanilla from the highway that shows a mix of construction types.  The 
dwellings on the hill, for instance, are mostly dirt floor, repurposed wood walled, corrugated 
metal roofed and have no electricity or running water.  Many of the dwellings in the foreground 
have electricity, although running water is more irregular. 
 
Tarmak, Lowfill (photographer). (2008). Ventanilla [photograph], Retrieved July 20, 2011, from: 
http://www.flickr.com/photos/lowfill/2527388108/ 
Some Rights Reserved (CC) BY-NC-SA 
 
This image shows the contrast of some of the simpler shack like dwellings often found on the 
hillsides, far from any paved road, and more developed cinder block and brick buildings in the 
background.  It can take ten years or more for a squatter settlement to get electricity and running 
water. 
Dool, Joshua (photographer). (2009). Ventanilla [photograph], Retrieved July 11, 2011, from: 
http://www.flickr.com/photos/61029434@N08/5590194586/ 
© all rights reserved; used with prior authorization from author for non-commercial use 
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View inside a home in Ventanilla. 
Cavero, Eduardo (photographer). (2008). Un Techo Para Mí País-Perú - Construcción en AAHH. Los Angelitos 
Ventanilla [photograph], Retrieved July 11, 2011, from: http://www.flickr.com/photos/eduardocavero/3169801200/ 
© all rights reserved; used with prior authorization for non-commercial use 
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APPENDIX E: List of Tier 1 Core Public Health Competencies Met 
Domain #1: Analytic/Assessment 
Identify the health status of populations and their related determinants of health and illness (e.g., factors 
contributing to health promotion and disease prevention, the quality, availability and use of health services) 
Describe the characteristics of a population-based health problem (e.g., equity, social determinants, 
environment) 
Use variables that measure public health conditions 
Use methods and instruments for collecting valid and reliable quantitative and qualitative data 
Identify sources of public health data and information 
Recognize the integrity and comparability of data 
Identify gaps in data sources 
Adhere to ethical principles in the collection, maintenance, use, and dissemination of data and information 
Describe the public health applications of quantitative and qualitative data 
Collect quantitative and qualitative community data (e.g., risks and benefits to the community, health and 
resource needs) 
Use information technology to collect, store, and retrieve data 
Describe how data are used to address scientific, political, ethical, and social public health issues 
Domain #2: Policy Development and Program Planning
Gather information relevant to specific public health policy issues 
Describe how policy options can influence public health programs 
Gather information that will inform policy decisions (e.g., health, fiscal, administrative, legal, ethical, social, 
political) 
Participate in program planning processes 
Identify mechanisms to monitor and evaluate programs for their effectiveness and quality 
Apply strategies for continuous quality improvement 
Domain #3: Communication
Identify the health literacy of populations served 
Communicate in writing and orally, in person, and through electronic means, with linguistic and cultural 
proficiency 
Solicit community-based input from individuals and organizations 
Participate in the development of demographic, statistical, programmatic and scientific presentations 
Apply communication and group dynamic strategies (e.g., principled negotiation, conflict resolution, active 
listening, risk communication) in interactions with individuals and groups 
Domain #4: Cultural Competency
Incorporate strategies for interacting with persons from diverse backgrounds (e.g., cultural, socioeconomic, 
educational, racial, gender, age, ethnic, sexual orientation, professional, religious affiliation, mental and 
physical capabilities) 
Recognize the role of cultural, social, and behavioral factors in the accessibility, availability, acceptability and 
delivery of public health services 
Respond to diverse needs that are the result of cultural differences 
Describe the dynamic forces that contribute to cultural diversity 
Describe the need for a diverse public health workforce 
Domain #5: Community Dimensions of Practice 
Recognize community linkages and relationships among multiple factors (or determinants) affecting health 
(e.g., The Socio-Ecological Model) 
Identify stakeholders 
Collaborate with community partners to promote the health of the population 
Maintain partnerships with key stakeholders 
Use group processes to advance community involvement 
Describe the role of governmental and non-governmental organizations in the delivery of community health 
services 
Gather input from the community to inform the development of public health policy and programs 
Inform the public about  policies, programs, and resources 
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Domain #6:Public Health Sciences
Describe the scientific foundation of the field of public health 
Identify prominent events in the history of the public health profession 
Identify the basic public health sciences (including, but not limited to biostatistics, epidemiology, environmental 
health sciences, health services administration, and social and behavioral health sciences) 
Describe the scientific evidence related to a public health issue, concern, or, intervention 
Retrieve scientific evidence from a variety of text and electronic sources 
Discuss the limitations of research findings (e.g., limitations of data sources, importance of observations and 
interrelationships) 
Describe the laws, regulations, policies and procedures for the ethical conduct of research (e.g., patient 
confidentiality, human subject processes) 
Partner with other public health professionals in building the scientific base of public health 
Domain #7: Financial Planning and Management
Describe the local, state, and federal public health and health care systems 
Describe the organizational structures, functions, and authorities of local, state, and federal public health 
agencies  
Adhere to the organization’s policies and procedures 
Report program performance 
Translate evaluation report information into program performance improvement action steps 
Apply basic human relations skills to internal collaborations, motivation of colleagues, and resolution of 
conflicts 
Domain #8: Leadership and Systems Thinking
Incorporate ethical standards of practice as the basis of all interactions with organizations, communities, and 
individuals 
Describe how public health operates within a larger system 
Use individual, team and organizational learning opportunities for personal and professional development 
Participate in mentoring and peer review or coaching opportunities 
Participate in the measuring, reporting and continuous improvement of organizational performance 
Describe the impact of changes in the public health system, and larger social, political, economic environment 
on organizational practices 
 
